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ABSTRACT 
Recently, it has been suggested that neurodevelopmental abnormalities 
underlie schizophrenia. However, it has also been suggested that schizophrenia 
is a neurodegenerative disease as evidenced by a progressive worsening of 
symptoms over time. Neurodevelopmental abnormalities may, therefore, 
create a functionally compromised system that is more susceptible to neuronal 
atrophy and/or death caused by environmental factors such as stress (a known 
precipitant of acute psychotic episodes and exacerbant of schizophrenia). This 
hypothesis was tested using the putative neurodevelopmental animal model of 
schizophrenia described by Lipska etal: (1993). This model, which parallels a 
number of aspects of schizophrenia, involves bilateral ibotenic acid lesions in 
postnatal day 7 male rats. The effects of neonatal hippocampal lesions on 
BDNF mRNA and NMDARl mRNA, factors involved in development, cell survival 
and cell communication, were investigated in adult rats following exposure to a 
physiological stressor. Apoptosis levels were also investigated in these rats to 
determine if neurodegeneration was present. 
Results demonstrate that BDNF mRNA was reduced in the prefrontal 
cortex and hippocampus of lesioned as compared to sham rats. Increased 
BNDF mRNA resulted from swim stress in both groups, but the increase in 
lesioned animals was more pronounced than controls. NMDARl mRNA was 
also reduced in the prefrontal cortex and CA3 and CAI regions of the 
hippocampus in lesioned venus sham rats. There was an increase, however, in 
the dentate gyrus of lesioned venus sham rats. Swim stress increased 
NMDARl mRNA in the prefrontal cortex and decreased it in the hippocampus. 
There was also an increase in apoptosis in lesioned versus sham rats, with no 
significant increase in response to stress. 
Reductions in BDNF mRNA in lesioned versus control animals support the 
hypothesis that neurodevelopmental lesions may result in a system more 
susceptible to stressors. Reductions in NMDARl mRNA are in accordance with 
the NMDA glutamate receptor hypofundion theory of schizophrenia. It is 
possible that reductions in glutamate function can remove the inhibitory effect 
of GABA, thereby resulting in overexcitation of the system and a potential for 
neurodegeneration. Increased apoptosis supports the presence of 
neurodegeneration as an ongoing phenomenon, however, it appears that these 
animals are resistant to increased cell death induced by acute stressors. The 
question remains whether chronic stress may have more serious consequences 
in these lesioned animals. 
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1.1 Characteristics of Schizophrenia 
Schizophrenia is a biological brain disease that affects approximately 1% 
of the world's population (Sartorius etd, 1972). The term schizophrenia, first 
coined by Bleuler (1950), refers to a break from reality caused by 
disorganization of mental functions such that thoughts and emotions cease to 
function normally together. Schizophrenia generally onsets between the ages 
of 17 and 30 in men and 20 to 40 in women (Carpenter & Buchanan, 1994). It 
is characterized by two major classes of symptoms, positive symptoms (the 
presence of something that should be absent) and negative symptoms (the 
absence of something that should be present) (Andreasen, 1995). Positive 
symptoms include hallucinations, delusions, disorganized speech, disorganized 
behavior and thought disorders. This category of symptoms has been 
subdivided into two classes, psychotic symptoms comprised of hallucinations 
and delusions, and cognitive symptoms comprised of thought disorders and 
disorganization of behavior and speech. These symptoms are generally the first 
recognizable symptoms of the disorder and are relatively treatable. Negative 
symptoms include blunted affect (decreased emotional expression), social 
withdrawal, avolition (loss of motivational drive), anhedonia (loss of ability to 
experience pleasure) and restricted speech. These symptoms are particularly 
disabling for persons with schizophrenia, as they are persistent, very difficult to 
treat and often prevent people from leading productive lives. 
Despite the prevalence and devastating effects of schizophrenia, very 
little is known about the underlying pathology. There has been shown to be a 
genetic component as evidenced by twin, family and adoption studies, but the 
results of these studies indicate that genetics is not the only factor involved in 
the expression of  schizophrenia. Family studies indicate that relationship to an 
affected individual results in an exponential increase in an individual's risk of 
developing schizophrenia (Karayiorgou & Gogos, 1997). Twin studies 
demonstrate a 50% concordance rate between monozygotic twins and a 4% to 
14O/0 concordance rate between dyzygotic twins (Farmer eCaL, 1987, McGuffin 
eta., 1995). Adoption studies also show that schizophrenia is more prevalent 
in biological relatives than in adoptive relatives (Karayiorgou & Gogos, 1997). 
The prevalence rates predicted by Mendelian genetics, however, are 
significantly higher than those seen in the population, therefore suggesting that 
other factors are integral to development of schizophrenia. It has been 
proposed that schizophrenia is associated with low penetrance variations in 
alleles that confer susceptibility to schizophrenia, but are not sufficient to cause 
the disease (Karayiorgou & Gogos, 1997). With the failure of genetics to 
completely account for schizophrenia, a number of theories based on 
neurochemical, neuropharmacological and neuropathological findings have 
attempted to explain the process behind schizophrenia, but still no one theory 
explains all facets of the disorder. 
1.2 Neurotransmitter Theories of Schizophrenia 
1.2.1 The Dopamine Hypothesis 
One of the first theories attempting to explain schizophrenia was a 
relative hyperactivity of central dopaminergic neurons (Matthyse, 1973, Snyder, 
1976, Stevens, 1973) projecting from the ventral tegmental area to limbic and 
cortical regions. Evidence for disruption of this system was inferred from 
pharmacological information. It was discovered that pharmacological agents 
used to treat schizophrenia were dopamine D2 receptor antagonists and that 
the efficacy of these drugs was directly correlated with D2 receptor blockade 
(Creese e t d ,  1976, Seeman etd, 1976). Further evidence was obtained 
from the demonstration that dopamine agonists such as amphetamine, L-DOPA, 
bromocriptine and lisuride induce acute psychotic reactions (Carlsson, 1988, 
Connell, 1958, GrifTith eld, 1972). Pharmacological evidence led researchers 
to search for direct evidence of dopaminergic involvement in schizophrenia. 
The first direct evidence was the finding of increased striatal Dz dopamine 
receptors in postmortem tissue from schizophrenic patients (Owen etaL, 1978). 
Controversy surrounds this observation, however, as the increase in D2 
dopamine receptors may be due to neuroleptic treatment. In  support of this, 
Farde eta/ (1987) found no alterations in dopamine D2 receptor density 
between drug-nalve schizophrenics and controls. The discovery of additional 
members of the D2-like dopamine receptor family and their affinity for some 
neuroleptics, led researchers to investigate if these receptors were altered in 
schizophrenia. It was discovered that the D4 dopamine receptor was elevated 
in the striatum of postmortem tissue from schizophrenic brains (Murray e t d ,  
1995). However, the alteration of this receptor type can also not be 
conclusively proven independent of neuroleptic treatment. 
The inconsistency of reports documenting the involvement of dopamine, 
combined with increased understanding of pharmacological treatment and 
knowledge of dopaminergic pathways in the brain led to a reformulation of the 
dopamine hypothesis of schizophrenia. The modified hypothesis states that a 
hyperdopaminergic state, resulting in positive symptoms, exists in the 
mesolim bic dopamine system and a hypodopaminergic state, resulting in 
negative symptoms, exists in the mesocortical dopamine system (Duncan el&, 
1999, Weinberger, 1987). Support for this hypothesis comes from earlier 
studies demonstrating that depletion of dopamine in the prefrontal cortex of 
monkeys results in cognitive deficits similar to those seen in schizophrenia 
(Brozoski e td ,  1979). Reductions in Dl dopamine receptor binding in the 
prefrontal cortex of drug nai've schizophrenic patients also provide evidence for 
mesocortical dopaminergic hypofunction (Okubo el&, 1997), however, this 
finding has not been replicated. 
Inconclusive findings in support of the role of dopamine in schizophrenia 
in conjunction with the inability of neuroleptics to effectively treat negative 
symptoms, leads to the conclusion that disruptions in the dopaminergic system 
cannot fully account for the plethora of symptoms and pathophysiological 
findings. Although dopamine is involved in schizophrenia it appears that it may 
be a resultant factor rather than a pathogenic factor. 
1.2.2 The Glutamate Hypothesis 
With the inability of dopamine to account for all of the various findings in 
schizophrenia, came the emergence of candidates previously overshadowed by 
dopamine. Glutamate, the major excitatory neurotransmitter in the central 
nervous system (Cotman & Iversen, 1987), became a major candidate primarily 
due to parallels between phencyclidine (PCP) psychosis and schizophrenia (for 
review see Javitt and Zukin, 1991 ). Phencyclidine was originally proposed as a 
model of schizophrenia in 1962 (Luby etal, 1962), although at this time its 
neurochemical action was not fully understood. It is now known that 
phencyclidine is a non-competitive NMDA glutamate antagonist (Anis etd,  
1983). In  its initial indication as an anaesthetic, phencyclidine produced a 
behavioral state characteristic of a dissociation from the environment although 
consciousness was retained (Collins et a/, 1960). For this reason, 
phencyclidine and its derivative, ketamine, were termed "dissociative 
anesthetics" (Corssen & Domino, 1966). I n  up to 50% of people treated with 
phencyclidine, psychotic reactions including bizarre behavior, excitation, 
hallucinations and paranoia resulted and persisted for several hours following 
anesthesia (Collins e td ,  1960). The administration of phencyclidine or 
ketarnine to patients with schizophrenia led to exacerbation of symptoms (Lahti 
etd, 1995b) and in stabilized patients led to the re-presentation of symptoms 
(Herexo-Levy etd, 1993). These effects persisted for days to weeks and 
were reported by patients to be characteristic of their non-drug induced 
symptoms (Lahti eta& 1995a). Ketamine has also been demonstrated to 
impair performance in psychological tests of prefrontal cortical function similar 
to what is observed in schizophrenia (Choneim etal, 1985, Oye e t d ,  1992). 
Further disruption of cognitive performance in schizophrenia is demonstrated by 
impairments in prepulse inhibition of startle, a paradigm for assessing deficits in 
information processing (Swerdlow et&, 1994). In this paradigm, a weak 
stimulus (the prepulse) is presented immediately before a startling stimulus 
(the pulse) and under normal circumstances, results in a reduction in the 
magnitude of response to the pulse (Hoffman & Ison, 1980). NMDA receptor 
antagonists have been demonstrated to mimic schizophrenia with respect to 
reductions in prepulse inhibition of startle (Geyer eta& 1990, Mansbach, 
1991). Possibly one of the most relevant parallels between schizophrenia and 
NMDA receptor antagonist administration is the age dependency relationship. 
Phencyclidine and ketamine are psychoactive in adults but not in children, 
therefore, similar to schizophrenia, there appears to be an age dependent 
vulnerability to psychosis (White e l  d, 1982). 
I n  addition to the convincing evidence of glutamate's involvement in 
schizophrenia as demonstrated by phencyclidine and ketamine, Kim e t d  
(1980) also proposed a role for glutamate in schizophrenia. Based on 
reductions in cerebrospinal fluid (CSF) glutamate levels in schizophrenic 
patients, it was hypothesized that a deficiency in glutamatergic function is 
associated with schizophrenia. This finding, in combination with the 
information regarding phencyclidine and schizophrenia prompted other 
researches to investigate the role of glutamate in schizophrenia. The 
demonstration of alterations of glutamate in the CSF could not be replicated 
(Korpi etd, 1987, Perry, 1982), however, Tsai e t d  (1995) found reductions 
of glutamate in the hippocampus and prefrontal cortex of postmortem 
schizophrenic brains. Decreases in stimulated release of glutamate in the 
frontal and temporal lobes of postmortem schizophrenic brains were also found 
(Sherman e td ,  1991a). Further analysis using synaptosomes prepared from 
schizophrenic brains demonstrated that NMDA stimulated release was 
specifically disrupted thus supporting a deficiency in glutamate transmission 
mediated by the NMDA receptor (Sherman e td ,  1991b). 
A third line of evidence for the involvement of glutamate in schizophrenia 
comes from binding studies and mRNA analysis. I n  1983, Nishikawa etar! 
reported increased 3~-kainate binding in the prefrontal cortex of patients with 
schizophrenia. In contrast to prefrontal cortex binding, 3~-kainate binding in 
the hippocampus and parahippocampal gyrus of schizophrenic patients was 
found to be significantly reduced (Kerwin eta/, 1990). AMPA (a-amino-3- 
hydroxy-5-methyl-4-isoxazole propionic acid) receptor (a non-NMDA ionotropic 
glutamate receptor) binding in the hippocampus of schizophrenic patients was 
also decreased in this investigation. In support of reduced binding, mRNA 
levels for kainate receptors and AMPA receptors were also found to be reduced 
in the hippocampus of schizophrenic patients (Breese eta/, 1995, Eastwood et 
d, 1995b, Harrison etd, 1991). The finding by Breese eta,! (1995), 
however, was no longer significant when alcohol abusers were removed from 
the control group. NMDA receptor binding in the hippocampus was reported to 
be unaltered (Kerwin etal, 1990, Kornhuber etd,  1989), whereas, both 
increases and no change have been reported in various cortical brain regions 
investigated (Ishimaru et al, 1994, Simpson et d, 1992). The possibility exists 
that controversial reports are, at least in part, a result of the schizophrenic 
population examined. Humphries e t d  (1996) reported a reduction in mRNA of 
the NR-1 subunit of the NMDA receptor in the temporal cortex in a cohort of 
patients with cognitive impairment. There was a direct correlation between 
NMDA receptor subunit expression and cognitive performance. Patients with no 
cognitive impairment did not show this alteration. A slight decrease in NMDA 
receptor subunit expression was also found in the frontal lobe (Hirsch eta/, 
1997). A screen of mRNA expression of the various subunits of the NMDA 
receptor in schizophrenic brains revealed no generalized abnormalities, 
however, abnormal increases in the relative levels of the NRZD subunit mRNA 
were found (Akbarian eta& 1996b). The NRZD subunit is a subunit of the 
NMDA receptor that has a lower threshold of activation and a prolonged rate of 
ionic current decay (Monyer eta/, 1994). Relative increases in this subunit in 
schizophrenia suggest that compensatory mechanisms for glutamatergic 
hypofunction may be in place (Akbarian etaL, 1996b). 
The ability of phencyclidine and ketamine to mimic or exacerbate 
fundamental characteristics of schizophrenia in association with alterations in 
binding and mRNA levels provide strong evidence for glutamatergic involvement 
in schizophrenia. The glutamatergic hypothesis is strengthened further by its 
ability to explain alterations in dopaminergic neurotransmission in 
schizophrenia. Glutamatergic efferents project from the cortex to subcortical 
dopaminergic cell bodies (Bjorklund & Lindvall, 1984, Sesack etal, 1989) and 
the prefrontal cortex receives reciprocal dopaminergic inputs (Bjorklund & 
Lindvall, 1984, Thierry eta/, 1973). In accordance with the hypothesized role 
of dopamine in schizophrenia, acute NMDA antagonist administration has been 
demonstrated to increase dopamine turnover and release in mesolimbic and 
mesocortical dopamine systems (Bubser eCaL, 1992). Subchronic NMDA 
receptor antagonist administration, possibly more relevant to schizophrenia, 
reduces dopamine in the prefrontal cortex (Jentsch e td ,  1997). Acute 
ketamine produces dopamine dependent impairments in prefrontal cortex- 
sensitive cognitive tasks that can be blocked by non-NMDA receptor antagonists 
and dopamine antagonists (Moghaddam e td ,  1997, Verma & Moghaddam, 
1996). It has been demonstrated, however, that NMDA antagonists can 
produce their effects independently of dopaminergic activity (Carlsson & 
Carlsson, 1989), but under normal conditions dopamine neurotransrnission 
contributes to the drug effects (Bubser el& 1992). These findings support a 
situation of dopamine dysfunction occurring downstream from glutamatergic 
dysfunction. 
1.3 I\leurodevelopmental versus Neurodegenerative Theories 
Other neurotransmitters have been implicated in the pathophysiology of 
schizophrenia as well, but strict neurotransmitter theories do not account for 
pathological reports. In addition, the limitations in symptom treatment by 
neuroleptics suggest neurotransmitters are not the primary disruption. The 
emergence of neuropathological data (see section 1.3.1) and consequent 
theories produced a paradigm shift in views on schizophrenia. In 1987, 
Weinberger (1987) first proposed a neurodevelopmental hypothesis of 
schizophrenia. This hypothesis states that schizophrenia is a primary brain 
disease resulting from a fixed structural defect occurring early in life and 
interacting with maturational events. These maturational events include 
neuronal and glial proliferation and migration, axonal and dendritic 
proliferation, myelination of axons, programmed cell death and synaptic 
pruning (Lieberman, 1999). A widely accepted model suggests that a 
neurodevelopmental insult results in altered morphology and cytoarchitecture 
and, therefore, a deficiency in the modulatory capacity of neurons (Duncan e l  
aL, 1999). During adolescence or early adulthood, this deficiency, in 
conjunction with environmental triggers, such as stress, leads to observable 
symptoms. This emergence is proposed to occur due to the elimination of 
synaptic connections that previously compensated for the deficiency. It has 
been demonstrated that obstetric complications, low birth weight (Cannon et 
d, 1989) and perinatal infections (Mednick etai, 1988) are positively 
correlated with the occurrence of schizophrenia. Minor physical abnormalities 
also lend support to a developmental correlate of schizophrenia (Waddington et 
al, 1990) as do the presence of childhood behavioral precursors such as 
withdrawn behavior and attentional problems (Baum & Walker, 1995, Done e t  
al, 1994, Jones eta, 1994, Walker & Lewine, 1990). Previous reports also 
suggest that structural defects are present at the onset of illness (DeLisi e t  d, 
1991, Weinberger etarl, 1982), are static (Illowsky e t d ,  1988, Lieberman e t  
al, 1992, Marsh etd, 1994) and are not associated with gliosis, a marker of 
neurodegeneration (Roberts etarl, 1986, Stevens e t d ,  1988). 
I n  contrast to these reports, others have suggested that schizophrenia is 
an ongoing degenerative process as evidenced by progression of symptoms 
(Fenton & McGlashan, 1994, Loebel e td ,  1992, Wyatt, 1991), structural 
defects (DeLisi etal, 1997, DeLisi eta& 1995,Jacobsen etd, 1998, Nair e t  
d, 1997) and increased gliosis (Stevens, 1982). These studies report that the 
length of time of symptom presentation prior to pharmacological treatment is a 
significant predictor of treatment response, relapse and long term outcome. 
Indications of disease progression led to the proposal that the biological defect 
in schizophrenia is a continual lifetime process of alterations in cell growth and 
repair most likely resulting from a genetic defed(s) (DeLisi, 1997). Aberrant 
neurodevelopment would lead to disorganization and dysconnectivity of 
neurons and subsequent cell loss (See Figure 1.1). 
I n  addition to clinical evidence for neurodegeneration, the involvement 
of glutamate, as outlined above, also supports a role for neurodegeneration. 
NMDA receptor antagonists, such as those used to model schizophrenia, have 
been shown to be neurotoxic (Olney etal, 1989). The extent of cell death is 
dependent on age as neurotoxic effects are only evident at the onset of puberty 
and become maximal in early adulthood (Farber e t d ,  1995). Repeated NMDA 
receptor antagonist treatment has been demonstrated to result in subtle but 
permanent changes in neocortical and limbic structures that are reminiscent of 
HYPOTHESIZED PATHOGENESIS OF SCHIZOPHRENIA 
I Life Span 
Defective Gene(s) 
u 
Periods of Brain Growth and Development 
Prenatal - 12 to 18 years 25 - 50 years + 
2 years 
Early 
neurodevelopmental 
defects 
Brain aging, 
neuronal and 
synaptic reduction 
(neu rodegeneration) 
Adolescent pruning 
and reforming of 
neuronal connections 
Figure 1.1. Hypothesis of the pathogenesis of schizophrenia suggesting 
schizophrenia is a lifetime disorder with a genetic defect resulting in 
neurodevelopmental and neurodegenerative components. 
Adapted from DeLisi, 1997. 
those observed in schizophrenia (Olney & Farber, 1995). These authors 
suggest that NMDA receptor hypofundion, as seen by NMDA receptor 
antagonist administration and as proposed in schizophrenia, exerts effects via 
the GABAergic system. NMDA receptor hypofunction may result in disin hi bition 
of excitatory pathways normally tonically inhibited by GABAergic neurons under 
the control of NMDA receptors. This could result in increased excitatory 
neurotransmission and, therefore, excitotoxic damage to neurons. This 
situation could result from either a defect in the glutamatergic system or by a 
defect in the GABAergic system. 
In  sum, evidence exists for both neurodevelopmental and 
neurodegenerative components in the pathophysiology of schizophrenia. These 
processes are not necessarily mutually exclusive but rather, it is possible that 
both components co-exist to produce the pathophysiology of schizophrenia. In 
addition, they are both attractive hypotheses in terms of their ability to 
accommodate neurotransmitter theories. Alterations in neurodevelopment or 
neurodegeneration would not likely occur without consequent alterations in 
neurotransmission. 
1.3.1 Neuropathological Findings in Schizophrenia 
1.3.1.1 Gross Morphological Abnormalities 
The first structural abnormality in schizophrenia, that of enlarged 
ventricles, was reported by Jacobi and Winkler (1927). The advent of 
computerized tomography (CT) allowed the confirmation of enlarged ventricles 
in schizophrenia (Johnstone eta/, 1976, Weinberger eta/, 1979). Johnstone 
et a1 (1976) also demonstrated that enlarged ventricles were significantly 
correlated with impairments in cognitive performance. These findings provided 
the impetus to search for further abnormalities that would provide a more 
complete understanding of the pathogenesis of schizophrenia. 
Gross morphological examination has revealed widespread alterations in 
brain structure in schizophrenic patients (See Table 1.1). These alterations 
include decreases in brain weight (Brown etd,  1986, Pakkenberg, 1987), 
decreases in cortical volume (Pakkenberg, 1987, Zipursky eta., 1992), 
alterations in subcom'cal structures (Bogerts etd, 1985, Jeste & Lohr, 1989, 
Pakkenberg, 1990) and abnormalities in sulcogyral parameters (3akob & 
Beckmann, 1986, Kulynych etal, 1997, Pfefferbaum e t d ,  1988). These 
findings lend support to the hypothesis that the primary defect in schizophrenia 
is a neurodevelopmentally derived structural abnormality that appears to affect 
multiple brain regions. In accordance with morphological abnormalities 
resulting in symptom presentation, alterations in cortical gray matter are 
positively correlated with cognitive impairment in schizophrenia (Andreasen e l  
arl, 1986). Further, there is evidence that frontal gray matter reductions are 
correlated more strongly with negative symptoms than are temporal gray 
matter reductions (Zipunky e t d ,  1992). Support for this possibility comes 
from a study demonstrating no significant difference in prefrontal gray matter 
in a cohort of schizophrenics with predominantly positive symptoms (Wible e t  
31, 1995). It is possible that although subtle abnormalities are seemingly 
universal in schizophrenia, morphological abnormalities are as heterogeneous 
as the symptoms expressed (Weinberger & Lipska, 1995). This heterogeneity 
and subtlety of morphological abnormalities may account for the lack of 
morphological alterations reported by a number of researchers. 
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BRAIN 
ABNORMAUTY REGION/PARAMETER 
Brain Weight Decreased 
I Cortical volume I I I Decreased 1 
11 (Cerebral Gray I 1 
Matter) 
Lateral Ventricle Increased 
volume 
volume 
Parahippocampal Decreased 
Region vol u me/a rea 
I Increased size 
Sylvian Fissure Shortened (left) 
Sulcogyral Patterns Abnormal 
Cortical Foldinq Reduced I/ Sulcal Width I Increased 
POSITIVE REPORTS 
Brown eta., 1986 
Pakkenberg, 1987 
Pakkenberg, 1987 
Zipursky eta., 1992 
Gur etarC, 1999 
Johnstone etal, 1976 
Weinberger eta., 1979 
Brown el&, 1986 
Pakkenberg, 1987 
Crow e t d ,  1989 
Detisi eta., 1995 
Suddath eta., 1989 
Menon etaL, 1995 
Barta eta., 1997 
bgerts etal, 1985 
Jeste & Lohr, 1989 
Barta etarC, 1997 
Bogerts eta., 1985 
Brown etaL, 1986 
Colter e t d ,  1987 
Falkai etal, 1988 
Altshuler eta., 1990 
Heckers eta., 1991b 
Lauer & Beckmann, 1997 
Pakkenberg, 1990 
Andreasen, 1994 
Crow etal, 1992 
Falkai eta., 1992 
Jakob & Beckmann, 1986 
Kulynych eta., 1997 
Pfefferbaum e l  d, 1988 
NEGATIVE REPORTS 
Heckers etarC, 1991b 
Heckers el&, 1991b 
Brown etal, 1986 
Altshuler et aL, 1990 
Bogerts eta., 1985 
Brown etal, 1986 
Table 1.1. Gross morphological alterations demonstrated in schizophrenic 
brains. 
1.3.1.2 Cytoarchitectonic Abnormalities 
The presence of macroscopic alterations in the brains of schizophrenic 
patients leads to the assumption that microscopic alterations co-exist and 
underlie these gross abnormalities. Numerous investigators (See Table 1.2) 
have reported widespread neuronal disruptions. There appears to be a general 
decrease in neuronal size in the hippocampus (Arnold etal, 1995), and various 
cortical regions (Arnold etd, 1995, Benes e t d ,  1986, Rajkowska e t d ,  
1998). A general decrease in neuron density is also reported to exist in 
various brain regions (Arnold etal, 1995, Benes etaL, 1986, Benes etal, 
1991, Falkai e t d ,  1988, Holinger eta& 1995, Jeste & Lohr, 1989). The 
prefrontal cortex, however, appears not to follow this pattern, as reports 
suggest increased pyramidal cell density in this region (Benes eta& 1991, 
Selemon e t d ,  1998, Selemon etd, 1995). No overall alterations in cell 
number are evident in the disorder (Pakkenberg, 1993), however, it is 
suggested that decreases in cell numbers exist in discrete brain regions, thus 
accounting for decreased cell density. Benes etaA (1991) reported a specific 
loss of interneurons in the prefrontal and cingulate cortices of schizophrenic 
patients. These decreases, however, are not dramatic enough to account for 
the significant reduction in cortical volume as seen in schizophrenic brains. This 
supports the concept that increases in cell density in the prefrontal cortex may 
involve cell loss but, this may co-exist with a reduction in neuropil, 
interneuronal material consisting of dendritic trees and axons (Selemon & 
Goldman-Rakic, 1999). I n  support of this hypothesis is the demonstration of 
reduced dendritic spines, sites of excitatory synapses on pyramidal neurons, in 
layer 111 pyramidal cells in the cortex of schizophrenic patients (Garey et al, 
1998, Glantz & Lewis, 1995). This indicates a reduction in the number of 
synapses formed in the prefrontal cortex. I n  addition to abnormal numbers 
and densities of neurons in the brains of schizophrenic patients, a number of 
alterations in neuron distribution have also been reported. Akbarian e td  
(1993a, 1996a, 1993b) reported alterations in nicotinamide adenine 
dinucleotide phosphate-diaphorase (NADPH-d) containing neurons in the 
temporal and frontal lobes of schizophrenic patients. NADPH-d is a neuron- 
specific enzyme present in both gray and white matter cell populations. I n  the 
white matter, NADPH-d containing cells remain from the subplate, a transient 
structure in neurodevelopment. Interstitial neurons of the adu It neocortical 
white matter, remaining from the subplate, are proposed to be involved in the 
establishment, maintenance and function of cortical circuitry (Chun & Shatz, 
1989). The decrease in NADPH-d positive neurons in gray matter and 
associated increase in subcortical white matter suggests a failure of neurons to 
appropriately migrate during neural development or a failure of appropriate 
programmed cell death (Akbarian etd, 1993a, 1996a, 1993b). Further 
support for aberrant neuronal migration is demonstrated by displacement of 
single groups of neurons in the entorhinal cortex of schizophrenic patients 
(Jakob & Beckmann, 1986). Hippocampal pyramidal cells also appear to be 
disorganized in schizophrenic patients (Scheibel & Kovelrnan, 1981), however, 
attempts to replicate this finding showed no significant differences overal I, but 
specific cases with more severe symptoms did show pyramidal cell 
disorganization (Altshuler e t  d, 1987). In accordance with 
neurodevelopmental abnormalities as a pathogenic factor in schizophrenia, 
hippocam pal neuronal disarray was more pronounced at the interface between 
hippocampal regions which are known to migrate at distinct developmental 
times. 
Neuropathological findings demonstrate that schizophrenia is a 
disease characterized by a large number of morphological abnormalities that 
appear to have their origins in neurodevelopmental abnormalities. 
Neurodevelopmentally derived alterations in neuronal structure and 
organization suggest that alterations in the expression of factors involved in 
neuronal migration, connectivity and viability may also be evident. 
BRAIN 
REGIONfPARAMETER ABNORMALITY POSITIVE REPORTS NEGATIVE REPORTS 
Superior Temporal 
Gyrus Neuron Density 
Hippocampal Neuron 
Density 
Decreased Holinger el&, 1995 
Decreased Jeste & Lohr, 1989 Heckers eta/, 1991a 
Decreased Hippocampal Neuron 
Size 
Entorhinal Cortex 
Neuron Densitv 
Arnold eta/, 1995 
Decreased Falkai etsl, 1988 
Krimer eta/, 1995 
Heckers etaL, 1991a 
Arnold etaL, 1995 
Entorhinal Cortex Decreased 
Neuron Size 
Prefrontal Cortex Decreased in Benes el& 1986 Akbarian etal, 1995a 
Neuron Density pyramidal cell 
layers 
Increased in Benes elall 1991 
Selemon etaL, 1995 
Selemon elal l  1998 
Rajkowska eta& 1998 
pyramidal cell 
layers 
Prefrontal Cortex 
Neuron Size 
Decreased 
Cingulate Cortex 
Neuron Density and 
Size 
Decreased in Benes eta/, 1986 
Benes etal, 1991 pyramidal cell 
layers 
Increased Striatal Neuron Counts Beckmann & Lauer, 
1997) 
Pakkenberg, 1990 
Pa kken berg, 1990 
Mediodorsal Thalamic 
Neuron Counts 
Decreased 
- - 
Table 1.2. Cytoarchitectonic abnormalities reported in schizophrenia. 
1.3.1.3 Biochemical Abnormalities in Schizophrenia 
Recent evidence indicates that alterations involved in neurodevelopment, 
neuronal connectivity and viability do exist in schizophrenia. A 115 kDa isoform 
of neural cell adhesion molecule (NCAM) is increased in the CSF (Poltorak e tA ,  
1995), hippocampus and prefrontal cortex of schizophrenic patients (Vawter et 
a/, 1998). NCAMs are memben of the immunoglobulin superfamily that are 
involved in axon guidance, cell migration and synapse stabilization, however, 
the 115 kDa isoform does not effectively mediate these actions. Rather, this 
isoform is a putative secreted protein that is potentially neurotoxic. Its increase 
in schizophrenia could be due to abnormal glial and/or neuronal processing or 
by structural abnormalities which would induce changes via cell loss where 
these molecules are localized (Vawter eta/, 1998). Increases in this soluble 
NCAM may have significant effects on synaptic plasticity and learning. Further 
evidence for alterations in NCAM was reported by Barbeau elaL, (1995) who 
demonstrated a reduction in polysialation of NCAM in the hilus region of the 
hippocampus. Polysialic acid (PSA) residues on NCAM increase interactions 
between multiple NCAMs, enhance the neurite growth promoting characteristics 
of NCAM and prevent aberrant neuronal connections during neurodevelopment. 
In adulthood, polysialated NCAM is present in areas that possess high degrees 
of plasticity such as the hippocampus (Miiler e l  d, 1993). Reductions in PSA- 
NCAM in schizophrenia may reflect abnormal neuronal connections between 
hippocampal neurons and may also have significant implications for 
hippocam pal connectivity to cortical regions (Barbeau et aL, 19%). The 
question remains whether alterations in PSA-NCAM exist throughout 
neurodevelopment and are a primary cause of the disorder or whether these 
alterations result from other abnormalities in schizophrenia. 
Other neurodeveiopmental factors altered in schizophrenia include 6- 
catenin and y-catenin (Cotter etd ,  1998). The catenins are memben of the 
Wnt signaling pathway, which are involved in cell adhesion, proliferation, 
migration and gene transcription. The Wnt family is a family of genes involved 
in normal neurodevelopmental processes such as neuronal migration (Dickinson 
elal, 1995) and neural crest expansion (Ikeya elal, 1997). Reductions in 6- 
catenin were found in the CA3 and CA4 region of the hippocampus and 
reductions in y-catenin were localized to the W region of the hippocampus. 
These changes could be associated with alterations in neurodevelopment or 
with alterations in synaptogenesis or transcription. 
Neurodevelopmental abnormalities are also implicated in schizophrenia 
by the demonstration of reduced reelin mRNA and protein in schizophrenic 
cortical regions (Impagnatiello etal, 1998). Reelin is a protein involved in the 
regulation of cortical pyramidal cell, interneuron and Purkinje cell positioning 
and/or trophic support during neurodevelopment (Curran & D'Arcangelo, 1998). 
Heterozygote reelin knockout mice show a similar reduction in reelin expression 
to that seen in schizophrenia. These mice show a number of neuroanatomical 
abnormalities reminiscent of those seen in schizophrenia (Impagnatiello e td ,  
1998). The abnormalities appear to be symptomatically silent with the 
exception of reduced prepulse inhibition of startle, a deficit also present in 
schizophrenia. A consequence of the neurodevelopmental abnormalities in the 
reelin deficient mouse appears to be an enhanced vulnerability to excitotoxicity. 
This may have implications for a neurodegenerative component in 
schizophrenia. 
Tumor necrosis factor alpha (TNF,), a cytokine involved in neuron 
growth and differentiation, also appears to be affected in schizophrenia. 
Increased plasma levels of TNF, were demonstrated in neuroleptic free 
schizophrenics as compared to controls (Monteleone e td ,  1997). This 
increase is specific to schizophrenia, as non-schizophrenic psychiatric patients 
showed no alterations in TNF,. Also, this increase was reduced by chronic 
clozapine treatment (Monteleone e td ,  1997). TNF, has also been 
demonstrated to have neurotoxic properties (Grell etal, 1994, Heller etaL, 
1992, Zheng etd, 1995) and, therefore, its increase in schizophrenia may 
have neurodegenerative as well as neurodevelopmental consequences. 
I n  accordance with neurodevelopmentally or neurodegeneratively 
induced alterations in interneuron number (8enes el&, 1991), alterations in 
glutamic acid decarboxylase (GAD) are also found (Akbarian etal, 1995a). 
GAD is the enzyme responsible for the synthesis of GABA from its precursor, 
glutamate. A decrease in GAD mRNA was demonstrated in the prefrontal 
cortex of schizophrenic patients thus suggesting a decrease in inhibitory 
neurotransmission in schizophrenia. The cortical layers most dramatically 
affected are those involved in corticocortical associative information processing 
which has significant implications for the negative symptoms of schizophrenia. 
Increased GAB& receptor binding in schizophrenia has also been reported 
(Benes el&, 1992). This could represent a compensatory upregulation 
thereby supporting reduced GABAergic neurotransrnission in schizophrenia. 
Alterations in GABAerg ic neurotransmission are hypothesized to result in 
relative increases in dopaminergic input to remaining GABAergic neurons in 
areas where GABAergic interneurons are lost (Benes etd, 1997). Evidence for 
this hypothesis is demonstrated by an apparent shift in the distribution of 
tyrosine hydroxylase (a marker of dopaminergic terminals) immunoreadive 
varicosities from pyramidal neurons to interneurons in the anterior cingulate 
cortex. This effect is selective to layer 11 of the cortex which is the major layer 
of interneuron loss (Benes el& 1991). This shift suggests a "miswiring" of 
dopaminergic inputs from the ventral tegmental area which could result in a 
relative, but not absolute, hyperdopaminergic state in relation to the impaired 
GABAerg ic interneuron population. 
Further evidence for disruptions in neuronal connectivity and 
transmission comes from the demonstration of altered synaptophysin in 
schizophrenic patients (Eastwood eld,  1995a, Glanb & Lewis, 1997). 
Synaptophysin is a protein located in the majority of cortical synaptic terminals 
(3ahn e t d ,  1985) and is considered to be a reliable marker of synaptic density 
(Masliah etd ,  1990). Eastwood etd,  (1995a) reported a reduction in 
synaptophysin mRNA in the hippocampus of schizophrenic patients. There was 
no change in hippocampal synaptophysin immunoreactivity, therefore, it was 
suggested that the loss of synapses is in extra-hippocampal sites that receive 
projections from neurons with reduced synaptophysin mRNA. In  accordance 
with this, subsequent reports demonstrated reduced syna ptoph ysin 
immunoreactivity in the prefrontal cortex, but not the visual cortex, of patients 
with schizophrenia (Glantr & Lewis, 1997). This reduction was not evident in 
non-schizophrenic psychiatric patients, nor in subjects with alcohol dependence, 
therefore, it appears to be relatively specific to schizophrenia. Reductions in 
synaptophysin in the prefrontal cortex suggest that either fewer synapses are 
present or that fewer vesicles are present per synaptic terminal. Regardless of 
the reason for the reduction, impairments in neurotransmission in the prefrontal 
cortex would be a significant consequence. Reductions in synaptophysin are 
also consistent with the hypothesis of reduced neuropil and increased neuronal 
density in the prefrontal cortex (Selemon & Goldman-Rakic, 1999, Selemon e l  
a& 1995). The reduction in synaptophysin is found across all cortical layers, 
therefore, it was proposed that GABAergic terminals, found in all cortical layers 
and responsible for corticocortical connections, may be those specifically 
affected (Glantz & Lewis, 1997). This suggestion is in accordance with 
alterations of the GABAergic system in schizophrenia as described above. 
Disruptions in neurotransmission are also evidenced by the 
demonstration of altered RNA editing of the GIuR-2 subunit of the AMPA-type 
glutamate receptor in schizophrenia (Akbarian etal, 1995b). The GluR-2 
subunit is a component of the AMPA receptor important for regulating calcium 
conduction. The edited form of the GIuR-2 subunit originally contains a 
glutamine codon that is posttranscriptionally edited to an arginine codon 
(Sommer etaL, 1991). This edited form normally constitutes more than 99% 
of the total GIuR-2 expressed and is responsible for restricting calcium 
permeability (Hollmann eta,,  1991, Verdoon et d, 1991). In  the prefrontal 
cortex of schizophrenics a significant increase in the ratio of unedited to edited 
GIuR-2 molecules was found thus suggesting increases in calcium permeability 
(Akbarian etd, 1995b). Increased calcium conductance has significant 
implications for neurotoxicity and in support of this, known neurodegenerative 
diseases such as Alzheimer's and Huntington's also show altered editing. The 
editing in Alzheimer's disease is decreased in the prefrontal cortex and in 
Huntington's disease, the effect is specific to the striatum. The effects in these 
diseases are also much greater than that seen in schizophrenia. It is not 
known if the alterations in editing are general or if they are specific to a 
subpopulation of neurons, thereby making a specific population more 
vulnerable to neurotoxicity. Recently, in the hippocampus, it has been 
demonstrated that GIuR-2 subunits are less abundant on GABAergic 
interneurons than on pyramidal cells thereby resulting in GABAergic 
interneurons having higher calcium permeability and potentially greater 
vulnerability to neurotoxicity (He e td ,  1998). I f  this pattern were also seen in 
the prefrontal cortex in combination with alterations in editing of GIuR-2 
subunits, greater support would be found for GABAergic cell loss and 
neurodegeneration in schizophrenia. 
Increasing evidence, other than imaging and clinical data, does suggest 
a role for neurodegenera tion in schizophrenia. Recently it was demonstrated 
that schizophrenics have increased plasma levels of S-100b protein (Weismann 
e td ,  1999). The concentration of S-100b protein, a calcium-binding protein 
found in the CNS, has been shown to increase in CSF and blood in proportion to 
CNS damage and therefore, is considered a marker of damage in patients with 
neurological disorders. This finding indicates ongoing neural damage in 
patients with schizophrenia. In  accordance with this are findings of increased 
superoxide anion production (Melamed et d, 1998) and reduced scavenging 
capabilities, thereby enhancing vulnerability to free radical damage. Reduced 
superoxide dismutase (SOD) activity has been demonstrated in neuroleptic 
naive, first episode patients (Mukhe jee etal, 1994) and reduced SOD mRNA in 
postmortem tissue of schizophrenics has also been reported (Lau etal, 1999). 
Glutathione has also been reported to be reduced in schizophrenic patients (Do 
el& 1999) as has glutathione peroxidase (Reddy & Yao, 1996). A deficit in 
glutathione is proposed to result in free radical induced neurodegeneration. 
Glutathione also potentiates the effect of glutamate at the NMDA receptor, 
therefore, its reduction could also contribute to NMDA receptor hypofundion. 
Increased lipid peroxidation, indicating free radical damage, has also been 
demonstrated in the blood of schizophrenic patients (Murthy etd,  1989). 
These findings, generally associated with poorer outcome, lead to the 
conclusion that oxidative stress leads to membrane abnormalities and neuronal 
dysfunction (Reddy & Yao, 1996). Further evidence for membrane 
abnormalities stems from the demonstration of decreased 
phosphomonoesterases, precursors of membrane phospholipids, and increased 
phosphodiesterases, breakdown products of membrane phospholipids 
(Pettegrew e t d ,  1990). This proposed decrease in synthesis and increase in 
breakdown of membranes in schizophrenia could be indicative of neuronal loss 
or loss of connections. 
In an attempt to further elucidate the potential role of 
neurodegeneration, m itochondrial function in schizophrenia was addressed. 
Mitochondria are responsible for energy production within cells and, therefore, 
play an important role in cell viability. Cavelier eta4 (1995) reported a 
reduction in cytochrome c oxidase, a mitochondria1 respiration enzyme and 
marker of mitochondrial function, activity in the frontal cortex and caudate 
nucleus of schizophrenics. It was proposed that this reduction reflected a 
general decrease in mitochondrial oxidative phosphorylation, and therefore, 
ATP production. Subsequently, another group investigated the number of 
mitochondria in the striaturn from schizophrenic and control postmortem tissue. 
It was reported that the striatal neuropil of schizophrenic patients contained 
significantly fewer mitochondria than did controls (Kung & Roberts, 1999). This 
suggests either decreased energy demands or a reduced capacity to meet the 
energy requirements of structures with fewer mitochondria. The majority of 
striatal terminals arise from cortical neurons, therefore, the suggestion was 
made that a decrease in energy exists in corticostriatal circuitry in 
schizophrenia. It remains to be determined if specific populations are effected 
and whether the mitochondrial reduction is present in other brain structures. 
Reduced energy supply, in combination with the above alterations, has 
significant implications for cell connectivity, neurotransmission and cell viability. 
Regardless of what the primary pathogenic factor is, it appears that 
neurodevelopment plays an important role, but many other factors are related 
to the expression of the disorder. No one theory on its own can explain the 
pathophysiology and heterogeneity of schizophrenia, but each explains various 
components. More recently, a holistic theory explaining how many of the 
abnormalities and hypotheses described interrelate to create the disease of 
schizophrenia has evolved (Weinberger & Lipska, 1995). 
1.3.2 The Dysconnectivity Hypothesis 
The dysconnectivity hypothesis originally proposed that symptoms of 
schizophrenia result from aberrant connections or from abnormal integration of 
information (Bunney eta& 1995, Friston & Frith, 1995, Weinberger & Lipska, 
1995). Historically, the name schizophrenia ("split mind") as coined by Bleuler, 
implied a cognitive dysconnectivity or a splitting of the mind from reality 
(Bleuler, 1950). The more recent dysconnectivity theory, however, is an 
anatomical theory with consequent cognitive dysfunction rather than a 
cognitive theory per se (Bunney etaL, 1995, Friston & Frith, 1995, Weinberger 
& Lipska, 1995). Reports of reduced spine density (Glanh & Lewis, 1995), 
reduced neuropil (Selemon & Goldman-Rakic, 1999), reduced synaptophysin 
(Eastwood etaL, 1995a, Glanh & Lewis, 1997) as well as abnormalities in 
cytoarchitecture and neurotransmission all suggest abnormalities in neuronal 
connectivity. 
Functional abnormalities also lend strong support to the dysconnectivity 
hypothesis of schizophrenia. Negative symptoms are thought to have their 
origin in the prefrontal cortex, a region of association cortex involved in 
motivation, planning and other higher cognitive functions. The prefrontal 
cortex also has reciprocal connections with other brain regions implicated in the 
pathophysiology of schizophrenia (Carr & Sesack, 1996, Sesack e t d ,  1989). 
Imaging studies demonstrate compromised functionality of the prefrontal cortex 
in schizophrenia as evidenced by reduced glucose metabolism in the prefrontal 
cortex of schizophrenics (Buchsbaurn eta& 1990, Cohen et aL, 1987). 
Reduced regional cerebral blood flow in the prefrontal cortex, with concomitant 
increases in blood flow in the occipito-temporal cortex, is also seen in 
schizophrenia (Ingvar & Franzen, 1974, Paulman e td ,  1990). Additional 
investigators (Berman e l d ,  1988, Weinberger etaL, 1986) also reported 
reduced prefrontal blood flow in schizophrenic patients versus controls 
however, this reduction was only seen during the Wisconsin Card Sorting Test, 
a cognitive test of dorsolateral prefrontal function requiring interactions 
between the prefrontal and tem porolim bic cortices. Findings of regional 
specificity in com bination with task dependency suggest functional 
dysconnectivity of circuitw relevant to schizophrenia (Wein berger & Lipska, 
1995). More recently, investigation of functional connectivity resulted in 
significantly different patterns between schizophrenics and controls again 
suggesting dysconnebivity between the frontal and temporal lobes in 
schizophrenia (Berman e ld ,  1999). 
Further evidence for dysconnedivity stems from a neurological model of 
schizophrenia. Metachromatic leukodystrophy is a genetic disorder of sulfatide 
metabolism resulting in abnormal development of intracortical connectivity 
(Polten e t d ,  1991). Demyelination results in disturbed but intact neuronal 
connectivity. Although the pathology is different in schizophrenia, many of the 
symptoms seen in schizophrenia are also seen in metachromatic 
leukodystrophy. At the onset of psychosis in metachromatic leukodystrophy, 
the demyelination is primarily in the prefrontal region, thus indicating that 
psychosis in this illness is related to a functional impairment in prefrontal 
connectivity (Hyde etd, 1991). Although this disorder does not address many 
characteristics of schizophrenia, it does support the concept that alterations in 
connectivity of neurons can result in schizophrenic symptoms. 
1.4 A Neurodevelopmental Animal Model of Schizophrenia 
1.4.1 Characteristics of the Model 
The widespread acceptance of the neurodevelopmental hypothesis of 
schizophrenia led to the establishment of a neurodevelopmental animal model 
of schizophrenia (Lipska e l l ,  1993). This model involves the use of ibotenic 
acid to bilaterally lesion the ventral hippocampus at postnatal day 7 (PND 7) in 
male Sprague-Dawley rats. Ibotenic acid is a glutamate analogue extracted 
from the mushroom Amanid muscztnb (Eugster e t d ,  1965) (See Figure 1.2). 
It has been shown to produce axon sparing lesions in the hippocampus with 
toxic effects to GABAerg ic and g lutamaterg ic intrinsic and projection neurons 
(Steiner et d, 1984). It causes relatively little damage as compared to surgical 
or electrolytic ablation which have been shown to damage adjacent areas, 
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Figure 1.2. Chemical structure of glutamate (A) and its 
excitotoxic analog, ibotenic acid (8). 
fibers passing through the hippocampus and vasculature (Jarrard, 1989). It is 
also a useful neurotoxin for use in neurodevelopmental models as it is able to 
induce lesions in immature brain structures. Kainic acid, another example of a 
glutamate analogue capable of producing excitotoxic lesions, is not toxic to 
neonatal animals, however, it has been demonstrate to result in apoptosis in 
the ventral hippocampus of adult animals (Contestabile et d, 1998). It is 
proposed that ibotenic acid exerts its effects through the NMDA receptor and is, 
therefore, not age dependent as NMDA receptors are expressed throughout 
development (for review see McDonald and Johnston, 1990). In  fact, 
hippocampal NMDA receptor binding has been demonstrated to be significantly 
higher from PND 4 to PND 9 than that seen in the adult hippocampus (Baudry 
el d, 1981). Kainic acid is proposed to act through non-NMDA ionotropic 
receptors which are not expressed at PND 7 (Steiner elal, 1984). For these 
reasons, ibotenic acid appears to be an ideal toxin for use in the development 
of this neonatal animal model. 
Post natal day 7 is relevant for a neurodevelopmental animal model of 
schizophrenia as the first week of post natal development in the rat 
corresponds to the second trimester of gestation in the human (Bayer, 1980). 
During the second trimester, neurons migrate and settle into their appropriate 
cortical sites (Rakic, 1988). Apparent neurodevelopmental abnormalities in 
neuronal migration during this period (see section 1.3.1.2) are proposed to 
result in the structural abnormalities seen in adulthood (Kerwin & Murray, 
1992). The second trimester is also the period of neurodevelopment coincident 
with maternal infections that correlate with the expression of schizophrenia 
(Mednick el a!, 1988). These factors indicate that rough parallels to the 
morphological features in schizophrenia may be able to be produced in a 
neurodevelopmental animal model. 
The ventral hippocampus, the region lesioned in the model, was chosen 
as it was deemed the region to most frequently show abnormalities in 
schizophrenia by Lipska and colleagues (1993). Evidence to support this 
conclusion comes from multiple sources (Altshuler etd ,  1990, Altshuler etal, 
1987, Arnold eta& 1995, Arnold eta/, 1991, Bogerts e ld ,  1985, Jakob & 
Beckmann, 1986, Jeste & Lohr, 1989). The ventral hippocampus is also 
relevant to schizophrenia as it has been shown to be responsible for 
hippocampal regulation of the mesolimbic dopamine system (Springer & 
Isaacson, 1982) as well as having connections with the prefrontal cortex 
(Ferino etal, 1987, Goldman-Rakic eta& 1984), the region implicated in 
negative symptom expression. Specifically, monosynaptic excitatory afferents 
project from the CAI  region of the hippocampus onto pyramidal neurons within 
the prefrontal cortex (Ferino etd,  1987, Laroche etal, 1990). In terms of 
neurodevelopment, the synaptic formation of the hippocampus is completed 
much earlier in development than cortical regions (Kostovic et aL, 1989). This 
implies that the hippocampus may demonstrate increased vulnerability to early 
stage developmental abnormalities (Kerwin & Murray, 1992). 
These factors discussed above all interact to produce a model of 
schizophrenia that is essentially a neurodevelopmental model of 
dysconnectivity. I n  effect, the ibotenic acid, during a period of critical 
neurodevelopment, results in deprivation of cortical and subcortical structures 
of their normal hippocampal connectivity (Weinberger & Lipska, 1995). This 
model, therefore, is in accordance with both the neurodevelopmental and the 
dysconnectivity hypotheses of schizophrenia. Whether consequent alterations 
in cell viability occur in adulthood, in support of the neurodegenerative 
hypothesis, has not been addressed. 
1.4.2 Parallels to Schizophrenia 
In an attempt to characterize the model, a number of parameters 
relevant to schizophrenia were originally investigated: dysregulation of 
dopaminergic systems, developmental/maturational dependency, frontal cortical 
dysfunction, vulnerability to stress, sensory gating (prepulse in hibition of 
startle), responsiveness to neuroleptic administration and genetic predisposition 
(Lillrank e l&  1995). 
Excitotoxic lesions in the ventral hippocampus of adult rats have been 
shown to result in enhanced spontaneous exploration with concurrent 
decreases in dopamine re!ease/transmission in the medial prefrontal cortex and 
the limbic system (Lipska e td ,  1992), areas innervated by the hippocampus 
(Ferino etal, 1987, Goldman-Rakic etd ,  1984). Animals lesioned as neonates 
show similar increases in spontaneous exploration (Lipska etaL, 1993), 
however, in vivo microdialysis indicates no alterations in basal dopamine levels 
in the prefrontal cortex or the nucleus accum bens (Lillrank et aL, 1996b). 
When rats with neonatal lesions are exposed to stress, however, contrary to 
sham animals, no increase is seen in extracellular dopamine. In addition, 
neonatally lesioned rats demonstrate an attenuated increase in dopamine levels 
in response to amphetamine challenge compared to sham animals. This finding 
was not replicated by Wan e t d  (1996), however, they did find an enhanced 
behavioral response to amphetamine challenge compared to sham animals. 
F urVler exploration to identify the subtype of receptor involved demonstrated a 
role for increased sensitivity of the dopamine Dz receptor subtype (Wan & 
Corbett, 1997), although specific isoforms of this receptor were not 
investigated. Lesioned animals demonstrate hyperresponsivity to quinpirole (a 
dopamine D2-like receptor agonist) as compared to sham animals, attenuation 
of amphetamine induced locomotion by raclopride (a dopamine D2 receptor 
antagonist), and show no differential effects with SKF38393 (a dopamine Dl 
receptor agonist). These findings suggest that animals with neonatal ventral 
hippocampal lesions have hyperresponsive/ hypersensitive dopaminergic 
systems, especially with respect to dopamine Dz receptors. This is especially 
relevant to schizophrenia as neuroleptics are thought to exert their effects, at 
least in part, through antagonism of D2 receptors (Creese eta/, 1976, Seeman 
etal, 1976). In addition, similar to schizophrenia, no overt alterations in the 
dopaminergic system have been identified but alterations are inferred based on 
behavioral and pharmacological responses (Lipska eta/, 1993). 
Of further relevance to schizophrenia is the demonstration that 
dopaminergic hypersensitivity only becomes evident after puberty. Rats tested 
at PND 35 (prepubertal) demonstrate normal behaviors and doparnine 
responsiveness whereas rats tested on PND 56 (postpubertal) demonstrate 
hyperresponsiveness (Lipska etd,  1993). The reason for the postpubertal 
onset is uncertain, however, it is not hormone dependent as animals castrated 
prior to puberty still demonstrate behavioral abnormalities (Lipska & 
Weinberger, 1994a). The timing of the neonatal lesion is critical to the delayed 
onset, as rats lesioned at PND 14, beyond the period of cell migration and 
settling, do not show the temporal onset of symptoms reminiscent of 
schizophrenia (Wood etd, 1997). 
In  addition to the inferred abnormalities in the dopaminergic system, 
further evidence for dysreg u lation of neurotransmission, comes from c-fos 
mapping studies. C-fos is an immediate early gene expressed in most neurons 
at low levels, and therefore, is a useful tool for identifying transynaptically 
activated neurons in various brain regions (Morgan & Curran, 1991). 
Amphetamine challenge, to which lesioned animals are behaviorally 
hyperresponsive as compared to sham (Lipska e t d ,  1993), results in a 
decreased expression of c-&sin lesioned rats as compared to sham in the 
prefrontal cortex and the striaturn (Lillrank et al, 1996a). This effect is seen at 
30 minutes post-challenge, but levels of c-fosare the same 90 minutes post- 
challenge. This suggests a delayed response although animals do have the 
ability to express c-fosat normal levels. It is proposed that this delayed 
response could negatively affect the expression of late-response genes that 
regulate neuronal activity. The c-fos response to amphetamine could 
conceivably be via activation of dopamine Dl receptors or inactivation of 
dopamine D2 receptors. This does not seem likely, however, as to obtain the 
observed c-fos response, receptor numbers would most likely be altered and 
previous binding studies demonstrated no alterations in dopamine Dl or D2 
receptors (Knable e l&  1994). It is also possible that the ability of 
amphetamine to promote dopamine release is impaired in lesioned animals 
(Lillrank e ld ,  1996a). Another possibility for the observed c4osresponse is a 
decrease in glutamatergic neurotransmission. The destruction of glutamatergic 
projection fibers in the ventral hippocampus may result in reduced glutamate 
release in innervated regions such as the prefrontal cortex. Consistent with 
reduced glutamatergic neurotransmission is the demonstration that rats with 
neonatal lesions are hypersensitive, in adulthood, to the effects of MK-801, an 
NMDA antagonist (Al-Amin e t  al, 1996). This observation is especially relevant 
as it demonstrates that other systems may be altered in the model and that 
dysconnectivity is almost certainly present and significant to impaired function. 
In addition, this observation brings the model one step closer to schizophrenia 
as these animals demonstrate hyperresponsivity to NMDA receptor antagonists. 
This is in accordance with the glutamatergic (NMDA receptor) hypofunction 
hypothesis of schizophrenia. 
Animals with neonatal lesions of the ventral hippocampus, unlike animals 
lesioned in adulthood, also demonstrate a hypersensitivity to stress (Lipska et 
d, 1993). Interestingly, animals with adult lesions in the medial prefrontal 
cortex show similar hyperresponsivity to stress (Jaskiw & Weinberger, 1992). 
The medial prefrontal cortex is known to play a role in stress and in the 
regulation of subcortical dopamine systems (Deutch etal, 1990). This leads to 
the conclusion that a neonatal lesion in the ventral hippocampus results in a 
loss of hippocampal - prefrontal connectivity and that this connectivity is 
essential for normal maturation of the prefrontal cortex (Lipska e t d ,  1993). 
There is evidence, in support of this conclusion, that the synaptic connectivity 
of the prefrontal cortex does not fully develop into adulthood (Kalsbeek etd, 
1988) (for review see Lewis, 1997). This conclusion supports the 
dysconnectivity hypothesis of schizophrenia and an important role for the 
postpubertal development of the prefrontal cortex in the emergence and 
presentation of symptoms. 
Various other behavioral abnormalities reminiscent of schizophrenia are 
also observed in animals with neonatal lesions of the ventral hippocampus. 
One such example is deficits in prepulse inhibition of startle as compared to 
sham animals, although the amplitude of the startle response in not different 
(Lipska e t d ,  1995). This effect is also dependent on development, as 
differences are seen in PND 56 animals but not in PND 35 animals. Lesioned 
animals treated with apomorphine, a dopamine agonist, also show an 
exaggerated reduction in prepulse inhibition as compared to controls. This 
provides furVler evidence for dopaminergic dysregulation in the model. A 
second example of behavioral abnormalities associated with schizophrenia and 
the model is social withdrawal (Sams Dodd et aL, 1997). Deficits in social 
interaction are classified as negative symptoms in schizophrenia, therefore, the 
social withdrawal in rats with neonatal lesions indicates that aspects of both 
positive and negative symptoms can be reproduced in the model. 
I n  addition to showing characteristics similar to schizophrenia, these 
animals with neonatal hippocampal lesions are also responsive to neuroleptic 
treatment (Lipska & Weinberger, 1994b). Low doses of both haloperidol and 
clozapine suppress spontaneous locomotor activity in lesioned animals, whereas 
only haloperidol suppresses locomotor activity in sham rats. Haloperidol, at a 
dose lower than that seen to cause immobility, rigidity or catalepsy was 
proposed to continuously block dopamine Dz receptors thereby inhibiting 
locomotor activity in both lesion and sham animals. It is suggested that 
clozapine may exert its actions in lesioned animals through receptors other than 
D2. Alternatively, its effects may be subthreshold in intact animals but the 
dysfunctional system set up by the neurodevelopmental lesion may be more 
susceptible to its effects. 
The final factor originally investigated in the model, genetic 
predisposition, also demonstrates parallels between the model and 
schizophrenia. A rat strain (Fisher 344) characterized by hyperresponsivity of 
doparnine systems to stress required a much smaller lesion to demonstrate 
abnormalities equivalent to Sprague-Dawley rats, the typical strain used (Lipska 
& Weinberger, 1995). In addition, a lesion of similar size to that seen in the 
Sprague-Dawley rats resulted in a much earlier onset of abnormalities. 
Contrary to this, rats (Lewis rats) with hyporesponsivity of dopamine show no 
abnormalities with typical lesions. This demonstrates that genetics can set up a 
predisposition for vulnerability to insults and can regulate the severity and 
expression of the defect. This suggests that genetics may play a significant 
role in the heterogeneous phenotypic expression of schizophrenia. 
1.4.3 Implications and Limitations of the Model 
This model demonstrates that a wide variety of factors associated with 
schizophrenia can be reproduced in an animal model, including doparnine 
dysregulation, prefrontal dysfunction, vulnerability to stress, behavioral and 
sensorimotor gating defects, responsiveness to dopamine antagonists and a 
genetic predisposition. It also demonstrates a potential dysregulation of other 
systems, such as the glutamatergic system, which is also relevant to 
observations in schizophrenia. Perhaps most importantly, however, it proves 
that the neurodevelopmental theory of schizophrenia is biologically possible, 
i.e., that a neurodevelopmental insult can result in consequences that manifest 
only after puberty (Lillrank eld ,  1995). 
There are a number of limitations associated with this model. Of 
primary concern is the fact that schizophrenia is a human disease affecting 
cognition, perception, behavior and emotion, therefore, the human condition is 
much more complex than could ever be seen in a rat model. The effects seen 
in the model, although proposed to result from neuropathology similar to 
schizophrenia, cannot be identical to symptoms seen in schizophrenia in 
humans. A second limitation is that the limited lesion produced in the rat 
model is still far greater than the subtle neuropathology seen in schizophrenia. 
Third, although genetic factors can be demonstrated to play a role, the specific 
causative factors that lead to aberrant neurodeveloprnent are not addressed in 
the model. Despite the limitations, this model allows for the exploration of a 
number of elements that would not be feasibly or ethically possible in a human 
patient. This includes elements such as mechanisms of neuroleptic action, drug 
testing, genetic - environmental interactions as well as time point studies of 
gene expression patterns. I f  extrapolations to the human condition of 
schizophrenia can be made, this model also has the advantage of being able to 
control more factors than is possible with a human population. 
1.5 Potential Factors Involved in Schizophrenia 
1.51 Stress 
A physiological stressor is defined as any external perturbation, or 
anticipation thereof, that results in a disruption of homeostasis (Sapolsky, 
1992). Exposure to stress results in a characteristic response of neural and 
endocrine alterations in an attempt to reestablish homeostasis. These 
responses include mobilization of energy, increase in cardiovascular tone to 
facilitate oxygen and glucose delivery to active tissues, suppression of 
digestion, growth, reproduction, and inflammatory and pain responses. I n  
addition, there is an alteration in cognition such that a sharpening of senses is 
demonstrated. Central to the stress response is the secretion of 
glucocorticoids, cortisol in the human and corticosterone in the rat. I n  general, 
adaptation to acute stress with minimal consequences is seen, but chronic 
stress can result in a disease process as the responses to stress become 
damaging over time (See Table 1.3). I n  particular, chronic or excessive 
exposure to glucocorticoids is especially damaging to h ippocampal neurons 
(Sapolsky etal, 1984, Watanabe etal, 1992, Woolley etd, 1990), an effect 
proposed to be mediated by glutamate via NMDA receptors (Armanini e l d ,  
1990). Chronic exposure to stress can result in dendritic atrophy as well as cell 
death. Lui eta1 (1996) also demonstrated that stress results in lipid 
peroxidation, protein oxidation and nuclear DNA damage in the cerebral cortex 
as well as the hippocampus. This suggests oxidative stress and subsequent 
neurodegeneration can be induced by physiological stress, at least in extreme 
conditions (8 hours of immobilization stress). I n  addition, dysregulation or 
reduction of glucocorticoid secretion can also result in damage due to an 
inability to appropriately adapt to stress (Sapolsky, 1992). The regulation of 
glucocorticoid secretion is under the control of the dorsal hippocampus 
(Feldman & Conforti, 1980) via a multisynaptic projection from the 
hippocampus to the paraventricular nucleus of the hypothalamus (Sa polsky, 
1992). This input inhibits the adrenocortical axis resulting in the downstream 
inhibition of glucocorticoid secretion (for review see Sapolsky, 1992). The 
hippocampus also mediates feedback inhibition, therefore, loss of corticosteriod 
receptors, due to compensatory downregulation, cell loss or aging, results in a 
hypersecretion of glucocorticoids and a potentially neurotoxic cascade. 
II STRESS RESPONSE 11 Mobilization of energy 
Increased cardiovascular tone 
Suppression of digestion 
Suppression of growth 
Suppression of reproduction 
Suppression of immune system 
Sharpening of cognition 
STRESS REIATED DISORDER 
Myopathy, fatigue, steroid diabetes 
Stress-induced hypertension 
- 
Ulczration 
Psychogenic dwarfism 
Amenorrhea, impotency, loss of libido 
Increased disease risk 
Neuron death 
Table 1.3. The stress response and consequent disorders from chronic 
exposure. Adapted from Sapolsky, 1992. 
As described, stress can result in serious consequences in a normal animal or 
human (for reviews see Sapolsky, 1992 and Selye, 1976), however, the 
ramifications are even greater in a person with schizophrenia. In addition to 
neurotoxic consequences of chronic stress, stress has been shown to 
exacerbate the symptoms of schizophrenia, as well as precipitate the onset and 
relapse of schizophrenia (Brown & Birley, 1968, Dohrenwend & Egri, 1981, Mari 
& Steiner, 1994). Dopamine and glutamate, neurotransmitters proposed to be 
involved in schizophrenia, are increased in the prefrontal cortex in response to 
stress (Abercrombie e t d ,  1989, Moghaddam, 1993, Thierry etd, 1976). The 
increase in dopamine is proposed to be due to the action of glutamate on 
prefrontal AMPA receptors as dopamine release is blocked by AMPA antagonists 
but not by NMDA antagonists in this region (Takahata & Moghaddam, 1998). 
I n  the ventral tegmental area, the origin of dopaminergic afferents to the 
prefrontal cortex, glutamate a b s  on both AMPA and NMDA receptors, to 
regulate dopamine release in the prefrontal cortex. This suggests that 
dysregulation of glutamate neurotransmission is upstream from dopamine 
dysregulation, and may result in the proposed abnormalities in dopaminergic 
neurotransmission in schizophrenia. These findings serve to integrate the role 
of stress in schizophrenia with the glutamate hypothesis as well as the 
dopamine hypothesis of schizophrenia. In  addition, it cannot be ignored that 
dysconnectivity, rather than strid dysregulation of glutamate, may result in 
enhanced responsivity to stress. 
1 S.2 Brain-Derived Neurotrophic Factor 
Brain-derived neurotrophic factor (BDNF), a member of the neurotrophin 
family, was first isolated from pig brain in 1982 (Barde etal, 1982) and was 
subsequently cloned and characterized in the rat and the human (Leibrock et 
d, 1989, Maisonpierre e t d ,  1991). BDNF is expressed in neurons throughout 
the brain with the highest levels found in the hippocampus (Ernfors etd, 
1990, Hofer etd, 1990, Wetrnore eta& 1990). More recently, however, it has 
been demonstrated that BDNF protein is not confined to neuronal cell bodies, 
but it is also found in neuropil, in both nerve terminals and preterminal axons 
(Conner etd, 1997). The absence of BDNF mRNA in protein rich neuropil 
suggests that BDNF protein is anterogradely transported by axons to terminal 
regions. 
From the BDNF gene, multiple mRNA transcripts are derived through the 
use of four different promoter sequences in combination with alternative 
splicing of exons within the 5' untranslated region of the gene (Timmusk el&, 
1993). Alternative promoters are responsible for developmental stage, tissue 
type and cell type specific expression. Exons I and I1 are specific to brain, exon 
111 is found in brain and heart, and exon N is abundant in heart and lungs with 
low levels in brain. The expression of BDNF is also dependent on the balance 
between the activity of the glutamatergic and GABAergic systems (Zafra etd, 
1990, 1991). Increased glutamate neurotransmission and reduced GABAergic 
neurotransmission are associated with increased BDNF expression. GAB& 
receptor antagonism results in a specific activation of promoters associated with 
exons I and I11 predominantly within the dentate gyrus of the hippocampus 
(Metsis el& 1993). I n  the neocortex, BDNF expression of exon I, I1 and I11 
transcripts is blocked by NMDA and AMPAfkainate receptor antagonists 
suggesting these receptors are involved in BDNF regulation in cortical regions. 
In the hippocampus, however, with the exception of the exon I11 transcript in 
the CAI region, NMDA receptor antagonism does not block BDNF expression. 
In fact, pretreatment with NMDA receptor antagonists potentiates the 
expression of BDNF exon I and I1 transcripts in the CA3 region and the dentate 
gyrus of the hippocampus. I n  addition, NMDA receptor antagonism has been 
shown to increase BDNF expression in the entorhinal, retrosplenial and 
cingulate cortices although transcript variants were not examined (Castren et 
al, 1993). These results demonstrate that each transcript shows regional 
variation in its expression pattern and regulation. This results in a complicated 
system of which the functional consequences are not yet known. 
In the hippocampus, cortex and in vitro, BDNF may regulate the survival, 
differentiation, morphology and synaptic remodeling of neurons (Alderson e l  
al, 1990, Ghosh etd,  1994, Jones e ld ,  1994, Korte e t d ,  1995, McCallister 
etal, 1995, Thoenen, 1995). It has also been demonstrated that BDNF may 
modulate neurotransmitter synthesis, metabolism and release, postsynaptic ion 
channel fluxes, neuronal activity and long term potentiation (Altar et a/, 1997, 
Croll eta/, 1994, Kang & Schuman, 1995, Thoenen, 1995). The association of 
BDNF with neurodevelopment, cell viability and synaptic strength make it an 
attractive candidate for involvement in schizophrenia. Support for a role for 
BDNF also stems from the demonstration that it is decreased by factors 
correlated with first episode onset such as stress (Smith etd, 1995a, 199513) 
and estrogen withdrawal (Singh etd,  1995). I n  addition, stress induced 
decreases in BDNF are blocked by 5-tiTz receptor antagonists, a receptor 
binding property of many neuroleptics (Vaidya e td ,  1997). Eledroconvulsive 
treatment (ECT), effective in treatment-resistant schizophrenia in corn bination 
with neuroleptics (Sajatovic & Meltzer, 1993), also upregulates the expression 
of BDNF (Lindefors etd,  1995, Nibuya etd, 1995). These findings lead to the 
inference that BDNF may be altered in schizophrenia. Direct investigations of 
BDNF in schizophrenia also suggest that it may be altered. Findings indicate 
that hippocampal BDNF mRNA is reduced (Brouha eta, 1996) as is serum 
BDNF in schizophrenic patients (Toyooka etal, 1999). An allele variant of the 
BDNF gene has also been identified in a population of schizophrenic patients 
(Vicente etal, 1996). These factors suggest that disruptions of BDNF may play 
a role in the etiology of this disorder by compromising neuroplasticity or altering 
neurotransmission. 
1.5.3 N-Methyl-D-Aspartate Glutamate Receptor 
Excitatory amino acids, primarily 1-glutamate and L-aspartate, are the 
major excitatory neurotransmitters in the brain, and as such, the most 
abundant neurotransmitter class in the mammalian brain (Cotman & Iversen, 
1987). These neurotransmitters exert their actions through two major classes 
of receptors: ionotropic (ion-specific transmembrane channels) and 
metabotropic (G-protein coupled) receptors. The ionotropic receptors can be 
further subdivided into NMDA, AMPA and kainate receptors (for review see 
(Hollmann & Heinemann, 1994, Nakanishi, 1992, Seeburg, 1993). NMDA 
receptors have been shown to play an important role in neurodevelopment 
(McDonald & Johnston, 1990), synaptogenesis (Constantine-Paton etaL, 1990), 
synaptic plasticity (Bliss & Collingridge, 1993), and excitotoxicity (Rothman & 
Olney, 1987). They have also been shown to have neurotrophic effects (Balazs 
e td ,  1988). The functions of NMDA receptors are mediated by characteristic 
receptor properties. NMDA receptors are characterized by high permeability to 
calcium, sodium and potassium. These receptors require glycine for activation 
(Johnson & Axher, 1987), they are activated by polyamines (Durand el& 
1992), and are inhibited by zinc (Nakanishi, 1992). I n  addition, NMDA receptor 
channels are blocked in a voltage-dependent manner by magnesium (Mori et 
al, 1992). NMDA receptors are multimeric complexes comprised of NMDARl 
and NMDARZ subunits, each with four transmembrane segments, that assemble 
in various combinations to produce various electrophysiological receptor 
properties (Nakanishi, 1992). There are four different NMDARZ subunits, 
responsible for modulation of NMDA receptor activity, encoded on four distinct 
genes. The NMDARl subunit is essential to the activity of the receptor and its 
mRNA is expressed in almost all neurons throughout the central nervous system 
with especially high levels in the hippocampus, cerebral cortex, cerebellum and 
olfactory bulb (Moriyoshi e ld ,  1991). Various isoforms of the NMDARl 
receptor, generated by alternative splicing of a single gene, also exist 
(Nakanishi e td ,  1992, Nakanishi, 1992); so far, nine have been identified 
(McBain & Mayer, 1994). These splice variants show differential spatial and 
temporal expression (Laurie & Seeburg, 1994), and pharmacological properties 
(Durand el&, 1992). To date, however, little is known about the expression 
profile and regulatory mechanisms of these splice variants. However, the 
multiple forms of NMDARl and NMDARZ and various possible combinations, 
lead to distinct receptor properties and the subsequent ability to differen tiall y 
regulate various functions and microenvironments. 
The extensive expression and function of NMDA receptors, in 
combination with reported alterations in glutamate neurotransmission and 
NMDA receptor antagonist sensitivity, make them likely candidates for 
abnormalities in schizophrenia. They influence neurodevelopment and neuronal 
viability and, therefore, alterations in neurodeveloprnent may result in the 
morphological and cytoarchitectural abnormalities observed in schizophrenia. If 
NMDA receptors are not a primary pathogenic factor, but rather are 
dysregulated as a consequence of other abnormalities, they still have significant 
implications for progression of the disease state. This conclusion is supported 
by the demonstration of neuroleptic regulation of various NMDA receptor 
subunits (Filzgerald etaL, 1995, Riva eld,  1997) and the fact that 
glutamatergic projections are the main projections connecting prefrontal and 
limbic structures (Cotman el&, 1987, Fagg & Foster, 1983), primary regions 
implicated in the pathophysiology of schizophrenia. 
1.5.4 Apoptosis 
Apoptosis is a tightly regulated genetic program for active cell death 
(Majno & Joris, 1995, Savill, 1994). It is engaged in a precise manner to 
achieve physiological cell clearance, such as that seen in neural pruning 
(Oppenheim, 1991). It is also becoming increasingly apparent that apoptosis is 
a factor in neurodegenerative diseases such as Alzheimer's disease (Stefanis et 
a,!, 1997). Abnormalities in the program of apoptosis, resulting in inappropriate 
time, place or quantity of cell death are proposed to  be the mediating factor in 
neurodegenerative disorders (Margolis etaL, 1994). Apoptosis is characterized 
by a morphological and biochemical profile distinct from that of necrosis, a form 
of cell death not tightly regulated (See Table 1.4) (for reviews see Majno and 
Joris, 1995, Wyllie etd, 1980, Sastry & Rao, 2000). Apoptosis is characterized 
by cell shrinkage, chromatin condensation, membrane blebbing and 
fragmentation of the cell into apoptotic bodies. Perhaps most characteristic, 
they also show a DNA fragmentation pattern of internucleosomal cleavage. 
Apoptosis can be induced by a wide variety of insults including ischemia 
(MacManus etd, 1993), glutamate excitotoxicity (Kure eta,!, 1991), NMDA 
antagonist administration (Johnson eta ,  1998, Zhang el& 1996), trophic 
factor withdrawal (Deckwerth & Johnson, 1993), oxidative stress and disruption 
of calcium homeostasis (Boobis e td ,  1989). For a comprehensive review of 
apoptosis refer to McConkey eta,! (1996). 
There has been no direct evidence of apoptosis in schizophrenia, but the 
suggestion of symptoms and morphological abnormalities progressively 
deteriorating over the course of the disease has led to the proposal that 
neurodegeneration, via a poptotic mechanisms occurs in schizophrenia (Coyle, 
1996, DeLisi, 1997, Margolis eta& 1994). This proposal is also supported by 
the demonstrated reduction in neurons in the prefrontal cortex (Benes etd, 
1991), the hippocampus (Jeste & Lohr, 1989) and in the thalamus (Pakkenberg, 
1990) of schizophrenics and is in accordance with the lack of gliosis in 
schizophrenics. The detection of apoptosis is not technically possible at this 
time in the brain of a living person, nor is postmortem analysis sufficient to 
identify if apoptosis is an ongoing phenomenon in schizophrenia. Therefore, 
until technology can overcome this obstacle, one is left to only speculate on a 
role for apoptosis in schizophrenia. 
11 CHARACTERISTICS 
Morphology 
Macromolecule Synthesis 
11 DNA Cleavage 
I Mechanism I Calcium 
i I. - - ' - '  ' 
APOPTOSIS NECROSIS 
I 
organelles intact I damaged organelles 
- 
- 
- 
- 
- 
- 
Reduced volume, 
chromatin condensation, 
Immune Response 
Typically essential; I Unnecessary, rapidly 
Increased volume, early 
membrane rupture, 
Normal development, I Hypoxia, hypothermia, 
increased early 
Internucleosomal pattern 
Cascade of genetically 
controlled events 
Moderate influx 
hormones, loss of trophic I complement attack, 
shut down 
No detectable pattern 
Loss of water and 
electrolyte balance 
Massive influx 
support I toxins 
Table 1.4. Comparison of apoptosis and necrosis as mechanisms of cell death. 
Adapted from Margolis etd,  1994. 
Phagocytosis Inflammatory response 
1.6 Objectives of the Project 
Many questions regarding the pathophysiology of schizophrenia remain 
unanswered and the limitations of investigations in human patients lead one to 
conclude that definite answers are still some distance away. The development 
of animal models, such as that developed by Lipska and Weinberger (Lipska el 
d, 1993), therefore, offer a great advantage as they provide an avenue for 
investigations not possible in humans. Although great care must be taken in 
ma king conclusions about schizophrenia from such models, significant advances 
can still be made. With the acceptance of the neurodevelopmental hypothesis 
of schizophrenia and consequent dysconnectivity comes the need to investigate 
factors that may be involved in neurodevelopment, neuronal and synaptic 
viability and neurotransmission, factors all proposed to be compromised in 
schizophrenia. The objectives of this research project were to investigate the 
expression of BDNF mRNA and NMDARl mRNA, both factors involved in 
neurodevelopment, cell viability and neurotransrnission, in animals with 
neurodevelopmental lesions of the ventral hippocampus. It was also of interest 
with respect to schizophrenia to investigate if these factors were differentially 
regulated in response to stress in lesioned versus control animals. A second 
major objective of this project was to determine if animals with developmental 
lesions modeling schizophrenia demonstrate increased apoptosis in the 
prefrontal cortex as compared to control animals. A second part of this 
question was whether or not animals with neurodevelopmental lesions show 
increased vulnerability to neurodegeneration induced by stress. 
The hypothesis tested was that neurodevelopmental abnormalities 
modeling schizophrenia create a fu nctionally compromised system with 
alterations in factors necessary for maintaining neuron viability and neuronal 
communication. The overall result would be a system more susceptible to 
neuronal atrophy and/or death caused by environmental factors such as stress. 
2. MATERIALS AND METHODS 
2.1 Chemicals 
All chemicals used were either reagent or molecular biology grade. All 
solutions were made with nanopure water, i.e. water purified by reverse 
osmosis, ion exchange and organic component removal (Barnstead RO pure 
and nanopure I1 with organic cartridge; Sybron Corp., Boston, Mass., USA.). 
Nanopure water used for in situ hybridization procedures was treated overnight 
with 0.1% diethylpyrocarbonate (DEPC) then autoclaved for 30 minutes. 
2.2 Animals 
Timed pregnant Sprague-Dawley rats were obtained from Charles River 
Canada (Montreal, Quebec, Canada) at 14 days gestation. All animals were 
housed in clear plastic cages at a room temperature of 19-21oC on a 12-hour 
light/dark cycle. Animals were allowed access to food and water ad libitum. All 
procedures involving animals were done in accordance with the guidelines of 
the Canadian Council on Animal Care and were approved by the University of 
Saskatchewan Animal Care Committee. 
2.2.1 Surgery 
Post-natal day (PND) 7 male rats were randomized to lesion or sham 
status and anaesthetized by hypothermia. Specifically, the pups were placed 
on wet ice for 5 minutes following which they were covered, with the exception 
of their head, with approximately 2 cm of ice and left for an additional 10 
minutes. This induced a state of anesthesia lasting approximately 30 minutes 
with no associated mortality. Xylocaine was applied to the head and an incision 
was made to expose the skull. The pups were placed in a modified neonatal 
stereotaxic apparatus (Cunningham & McKay, 1993). Bilateral injections of 1.5 
pg (f )-ibotenic acid (RBI, Natick, MA, U.S.A.) in 0.3 pl of artificial cerebrospinal 
fluid (ACSF; 124 mM NaCI, 5 mM KCl, 2 mM CaCI2-2Hz0, 1 mM MgCI2, 1mM 
NaH2P04, 24 mM NaHC03 and 11 mM D-glucose) (lesion) or ACSF alone (sham) 
were infused into the ventral hippocampus (AP -3.0, ML k3.5, VD -5.0 relative 
to bregma) at a flow rate of 0.15 pl/minute. The delivery system consisted of a 
10 pl removable needle Hamilton syringe (Chromatographic Specialties, 
Brockville, Ontario, Canada) attached to fused silica tubing (0.4 mm outer 
diameter, 0.2 mm inner diameter; Chromatographic Specialties, Brockville, 
Ontario, Canada). A microinfusion pump (MA 100, Medicin, Stockholm, 
Sweden) controlled delivery. The tubing was left in the brain for 4 minutes 
following completion of the delivery to allow for diffusion. Simple interrupted 
sutures were used to close the incision and the pups were allowed to recover in 
a 370C humid chamber. Following recovery they were returned to the mother. 
Rats were weaned at PND 25 and housed in groups of 4 with 2 lesion and 2 
sham per cage. 
2.2.2 Behavioral Testing 
At PND 35 and PND 56 rats underwent open field locomotor activity 
testing. Rats were placed in a 36 cm X 36 cm X 23 cm clear Plexiglas test box 
positioned inside a Columbus Instruments infra-red photobeam recording 
device consisting of a 12 X 12 photobeam grid. The photobeam device was 
interfaced with an Apple 11+ computer that recorded photobeam breaks as a 
measure of locomotor activity over time. At each age, the locomotor activity of 
each animal was recorded for 60 minutes. Test chambers were cleaned with 
70% ethanol before each trial. 
2.2.3 Stress Paradigm 
At PND 75 lesion and sham animals, in groups of 4, were exposed to 
either a stress or a non-stress condition. The stress condition was a forced 
swim test consisting of 15 minutes in 30 cm of 250C water. The control 
environment was identical to the swim environment with the exception that 
bedding material was placed in the bottom of the cage instead of water. Test 
cages were made of opaque plastic measuring 55 cm x 42 crn x 42 cm. 
Following the forced swim test, open field locomotor activity (as described 
above) was monitored for 90 minutes. 
2.2.4 Perfusion 
Twenty-four hours post-stress, animals were transcardiall y perfused with 
200 ml 0.1 M phosphate buffered saline (PBS) at pH 7.4 followed by 250 ml4% 
paraformaldehyde (PFA) in 0.1 M (PBS). Brains were removed, cut into two 
blocks (one containing the prefrontal cortex and the other containing the 
hippocampus), post-fixed in 4% PFA in 0.1 M PBS for 3 hours then 
cryoprotected in 3Oo/o sucrose in 0.1 M PBS a t  40C. Following cryoprotection, 
brains were flash frozen in isopentaneldry ice at -500C and stored at -700C. 
2.3 Tissue Processing 
2.3.1 Poly-L-lysine Coating Procedure 
Poly-L-lysine (Sigma Chemical Co., St. Louis, MO, U.S.A.) was diluted to 
a 0.1% solution (1: 10 v/v) in diethylpyrocarbonate (DEPC) treated water. 
Precleaned J Melvin Freed microscope slides (VW R, Mississauga, Ontario, 
Canada) were dipped for 5 minutes in O.lO/o poly-L-lysine, allowed to dry at 
600C, dipped a second time for 5 minutes and allowed to dry at 60% again. 
Slides were stored 40C. 
2.3.2 Sectioning 
At least one hour prior to sectioning, poly-L-lysine coated slides and 
brain blocks were equilibrated in a Shandon cryostat set at -22oC. Brain blocks 
were mounted with OCT embedding compound (WVR, Mississauga, Ontario, 
Canada) and 10 pm sections through the prefrontal cortex and the 
hippocampus were generated. Sections were thaw mounted onto poly-L-lysine 
coated slides in a rotating order such that each slide had one section from each 
of the four conditions and on sequential slides each of the four conditions were 
represented in each of the positions available on the slides. Sections through 
the hippocampus designated for histological staining were collected at 100 pm 
intervals and thaw mounted onto poly-L-lysine coated slides. 
2.3.3 Histology 
Sections through the ventral hippocampus were stained with 
haematoxylin and eosin (H&E). Sections were rehydrated through descending 
ethanols, stained 5 minutes in Harris' haematoxylin (Sigma Chemical Co., St. 
Louis, MO, U.S.A.), washed in tap water, differentiated in acid alcohol (95% 
ethanol containing 1% v/v HCI) then rinsed. Sections were counterstained in 
eosin solution containing 1 part stock (0.8% w/v erythrosin, 0.1% w/v eosin Y, 
0.l0/0 w/v eosin B and 0.2O/0 v/v glacial acetic acid) and 3 parts 80% ethanol, 
rinsed, dehydrated through ascending ethanols, cleared and mounted with 
D.P.X. Neutral Mounting Medium (Aldrich Chemical Co Inc., Milwaukee, WI, 
U.S.A.) 
Sections through the ventral hippocampus were evaluated for animal 
inclusion or exclusion based of the following exclusion criteria: damage in ACSF 
treated animals, damage outside 'the hippocampus in ibotenic acid treated 
animals, unilateral damage in ibotenic acid treated animals or lack of damage in 
ibotenic acid treated animals. Animals were also excluded if they demonstrated 
convulsive behavior. 
2.3.4 BDNF and NMDARl Probe Preparation 
2.3.4.1 BDNF and NMDARl cDNA 
BDNF cDNA in pBluescript SK-, designated pSK-rB(Cl), was obtained 
from Dr. Ron Lindsay (Regeneron Pharmaceuticals, Tarrytown, NY, U.S.A.). Rat 
NMDARl cDNA in pBluescript SK-, designated pNMDAR1-la, was obtained from 
Dr. Jim Boulter (The Salk Institute, San Diego, CA). pSK-rB(C1) contained an 
1127 base pair sequence of rat BDNF cDNA encoding prepro rat BDNF and 
mature rat BDNF, useful for the detection of all alternative mRNA transcripts of 
the BDNF gene. This sequence was cloned into the Ecdl l  polylinker site of 
pBluescript SK-. pNMDAR1-la contained a 4183 base pair sequence containing 
the coding region of the rat glutamate receptor subunit gene NMDAR1-la. This 
sequence was inserted between the Eca1 (53 and the Xhd (3') sites of the 
polylinker region. Both of the designated clones contained the gene for 
ampicillin resistance as well as promoter sites for T7 and T3 RNA Polymerase 
enzymes (See Figure 2.1). 
2.3.4.2 Preparation and Transformation of Competent Bacteria 
LB (Luria-Bertani) medium (1% w/v bacto-tryptone, 0.5% w/v bacto- 
yeast extract, 0.1% w/v NaCI, pH 7.4) containing 1.5% w/v agar was poured 
into tissue culture plates and following solidification, plates were inoculated 
with E cui JM109 and incubated a t  370C until distinct bacterial colonies could 
be identified. A distinct colony was removed from the plate and transferred to 
40 ml of sterile LB medium and placed in a shaking water bath at 370C. The 
optical density of the bacterial suspension was monitored at 600 nm until 0.4 
O.D. was obtained. At this time, the bacteria were collected by centrifugation 
NMDARl encoding region I 
XhoI 
I Prepro BDNF Mature BDNF 
Ecm1 
Figure 2.1. Structure of the pBluescript-SK plasmid (A) with the 
multicloning site (MCS) expanded to show the restriction digest sites 
surrounding the RNA Polymerase T7 and T3 promotor sites (B). C and 
D depict the NMDAR1-la cDNA and BDNF cDNA inserts, respectively. 
at 2500 x g at room temperature and resuspended in 4 rnl of 50 mM CaCI2. 
The volume of the suspension was brought to 20 ml with CaClz solution and the 
suspension was incubated on ice for 30 minutes to produce competent bacteria. 
Competent bacteria were collected by centrifugation at 2500 x g for 5 minutes 
at 40C then resuspended in 4 ml ice cold CaC12 solution. Ten nanograms of 
either pSK-rB(C1) or pNMDAR1-la were incubated for 20 minutes on ice with 
200 pl of competent JM109. The bacteria were heat shocked at 420C for 2 
minutes then incubated in 1 ml of LB medium for 45 minutes at 370C to allow 
for expression of antibiotic resistance. The resulting suspension was plated 
onto LB agar plates containing 0.05 mg/ml ampicillin for selection of transfected 
JM109. Untransformed JM 109 were plated separately on ampicillin plates as a 
negative control. Plates were incubated overnight at 370C to allow colonies to 
form. A single colony was transferred to 100 ml of LB medium and allowed to 
grow in a shaking water bath at 370C overnight for amplification of the plasmid 
and bacteria. 
2.3.4.3 Amplification and Isolation of pSK-rB(C1) and 
Transformed bacterial cells were collected by centrifugation, 
resuspended and lysed in O.2M NaOH containing 1% (w/v) SDS. Cell debris 
was removed and the plasmid DNA was precipitated with isopropanol. Proteins 
and lipids were removed by SS-phenol (salt-saturated phenol) and (1:24) 
isoamyl alcohol:chloroform extraction. Plasmid DNA was ethanol precipitated, 
washed, air dried and resuspended in water. 
2.3.4.4 Purification of the Plasmid DNA 
The plasmid DNA was combined 1:l with DNA loading buffer and ran on 
a 1% agarose gel containing ethidiurn bromide. Plasmid DNA was excised from 
the agarose gel and purified using a Geneclean I1 kit (BIO 101 Inc., LaJolla, CA, 
U.S.A.). Approximately 0.3 g aliquots of agarose were transferred to eppendorf 
tubes and 3 volumes of NaI solution were added. Tubes were placed in a 500C 
waterbath to dissolve the agarose. Glassmilk (an insoluble silica matrix) was 
added to adsorb the DNA. The mixture was placed on ice for 5 minutes with 
periodic vortexing. The Glassmilk was collected by pulse centrifugation and the 
supernatant was removed. Plasmid DNA was eluted with water and its 
concentration was determined by measuring the absorbance at 260 nm and 
using the following equation: 
DNA (pg/pI) = A260 x EC x DF 
where: A260 is the absorbance a t  260 nm, EC is the extinction coefficient of DNA 
(0.05 pg/pI) and DF is the dilution factor. 
2.3.4.5 Restriction Digestion of pSK-rB(C1) and pNMDAR1-la 
Mini-digests were performed on 1 pg of plasmid DNA to map the 
plasmids and test the efficacy of the restriction enzymes. pNMDAR1-la was 
mapped using 6bmI and ApaI. pSK-rB(C1) was mapped using 6bnMI and 
X Once the identities of the plasmids were verified, large scale restriction 
digests were carried out to produce probe templates. pNMDAR1-la was 
linearized with 6bnMI to produce an antisense probe template and with Apal to 
produce a sense probe template. pSK-rB(C1) was linearized with 6bnMI to 
produce an antisense probe template and with XhcI to produce a sense probe 
template. All reactions were incubated overnight at 370C, the enzymes were 
heat inactivated and completion of linearization was confirmed by 1% agarose 
gel electrophoresis with ethidium bromide. Concentrations of the templates 
were determined by measuring the absorbance a t  260 nm, and dilutions were 
carried out to make the final concentration approximately 0.5 pg/4 pl. Four pl 
aliquots of the probe templates were stored at -2OQC. 
2.3.4.6 Radiolabeling RNA Probes 
Radiolabeled RNA probes were transcribed from cDNA templates using 
T7 RNA Polymerase (Pharmacia Biotech, Uppsala, Sweden) (antisense) or T3 
RNA Polymerase (Pharmacia Biotech, Uppsala, Sweden) (sense). Prior to 
labeling, T7 and T3 RNA Polymerase enzymes were diluted to a concentration 
of 10 units/pI in 20 mM K2HP04/KH2P04, pH 7.5, 20 mM NaCI, 1 mM EDTA, 1 
mM DTT, 100 pg/ml BSA and 5% v/v glycerol. The labeling reaction was 
performed using 0.5 pg template DNA, 0.5 mM ATP, GTP and UTP (Pharmacia 
Biotech, Uppsala, Sweden), 1X transcription buffer (400 mM TrismHCl, pH 8.0, 
60 mM MgCI2, 100 mM DTT and 20 mM spermidine), 2 units/pI RNAguard 
(Pharmacia Biotech, Uppsala, Sweden), 0.5 units/pI T7 or T3 RNA Polymerase, 
8 pM CTP and 50 pCi 3 5 ~ a - ~ ~ ~  (Dupont NEN, Boston, MA, U.S.A.). The 
reaction was incubated at 370t for 2 hours then heat inactivated (650C for 15 
minutes). Ten units of DNase I was added to the reaction mixture and 
incubated for 45 minutes at 370C. Following template degradation, 10 pl of 
0.05 M EDTA and 65 p1 of STE buffer (NaCI-Tris-EDTA) The probe was purified 
on a Bio-Spin Chromatography Column (Bio-Rad Laboratories, Mississauga, ON) 
containing a Bio-Gel P-6 matrix then the activity was measured in an LS5000TD 
Liquid Scintillation Counter (Beckman Instruments, Fullerton, CAI U.S.A.). 
2.3.4.7 Preparation of Probes for In Situ Hybridization 
Hybridization buffer (0.6 M NaCI, 0.08 M Tris, pH 7.5, 0.004 M EDTA, 
0.1% w/v sodium pyrophosphate, 10% w/v dextran sulfate, 0.2% w/v SDS, 
0.02O/0 w/v heparin sodium salt, 50% v/v ultraformamide) was added to the 
probe to produce a final activity of -92 X lo6 cpm/40 pI. The mixture was 
boiled for 5 minutes, D l T  was added to a final concentration of 100 mM and 
the probe was placed on ice. 
2.3.5 Detection of mRNA by In  Situ Hybridization 
2.3.5.1 Theory of In Situ Hybridization 
In situ hybridization is a technique used to detect specific RNA or DNA 
species in tissue sections through the use of RNA (or DNA) probes 
complementary to the species of interest. This technique has the advantage of 
investigating discrete brain regions that are difficult to dissect out or do not 
contain sufficient RNA for other detection methods (Wilcox, 1993). A second 
advantage is the ability to investigate mRNA expression at the cellular level. 
This allows for differentiation of cell populations expressing the species of 
interest. In situ hybridization is also compatible with immunohistochemical 
techniques thus allowing for the specific identification of cell types expressing 
the gene of interest. In  addition, multiple detection methods including 
radioisotopes, non-isotopic fluorochromes or enzymatic conjugates allow for the 
simultaneous detection of multiple species (Bresser & Evinger-Hodges, 1987). 
Despite the many advantages of in situ hybridization over other nucleic acid 
hybridization techniques, there are also a number of limitations associated with 
this technique. Limitations include the inability to assess transcription rates or 
stability of transcripts. The technique is also limited by the artificial, static 
conditions within the tissue as the sections are fixed and processed to ensure 
optimum hybridization conditions. The choice of fixative can dramatically alter 
the sensitivity of the technique and optimization of fixation should be performed 
for each cell or tissue type (Bresser & Evinger-Hodges, 1987). The procedure is 
sensitive, but is dependent on investigator technique as the sections must be 
morphologically intact following multiple processes including perfusion, brain 
removal, freezing, sectioning, thaw mounting, prehybridizing, hybridizing and 
washing. In  situ hybridization is also time consuming and labor intensive 
especially when considering the multiple controls necessary to establish a 
sensitive, specific and reproducible protocol (Bresser & Evinger-Hodges, 1987). 
Hybridization is a reversible process that occurs through hydrogen 
bonding between complementary nucleotide bases of single stranded RNA or 
DNA molecules. Three possible hybrids are formed: RNA: RNA, DNA:RNA and 
DNA:DNA. RNA: RNA hybrids are the most stable whereas DNA:DNA hybrids 
are the least stable. I n  addition to the type of hybrid, the stability of the duplex 
formed is determined by the length of the probe, the degree of 
complementarity to the sequence of interest, the composition of the sequences, 
the temperature of hybridization, and the pH and the ionic strength of the 
hybridization buffer (Emson, 1993). Long sequences with high degrees of 
complementarity are more stable than shorter sequences or those containing a 
number of nucleotide mismatches. Duplexes containing higher incidences of G- 
C base pairs are more stable than are those containing more A-T (U) base 
pairs. This is because base pairing between guanine and cytosine is stabilized 
by three hydrogen bonds whereas adenine - thymine (uracil) base pairings are 
stabilized by only two hydrogen bonds. High temperature, low salt 
concentration and alkaline pH are considered high stringency conditions (Tecott 
etal, 1994). Stringency is a measure of the ability of single stranded 
molecules to appropriately associate with molecules of high complementarity. 
High stringency conditions favor the formation of specific interactions between 
the probe and the species of interest. This results in a high signal to noise 
ratio. High salt concentrations interfere with the electrostatic repulsion forces 
between negatively charged nucleic acid molecules, therefore, allowing non- 
specific associations. Low salt concentrations do not interfere with electrostatic 
forces so only those sequences with high complementarity can overcome the 
electrostatic repulsion to form stable hybrids. pH influences stringency by 
altering ionization states of molecules. An acidic pH neutralizes phosphates 
which are negatively charged at near neutral pH. This allows for association of 
non-complementary strands. An alkaline pH increases ionization, thereby 
promoting electrostatic repulsion and the association of sequences with high 
degrees of complementarity. Formamide can also be used to increase 
stringency as it reduces the temperature necessary for disassociation of non- 
complementary hybrids by destabilizing hydrogen bonds. 
2.3.5.2 Prehybridization 
Sections were rehydrated in 0.1 M PBS (pH 7.4), acetylated for 10 
minutes in 0.1 M triethanolamine containing 0.25% acetic anhydride to prevent 
electrostatic interactions between the probe and the proteins, washed in 2X 
SSC, dehydrated in ascending ethanots, delipidated 2 X 5 minutes in 
chloroform, transferred to 100% ethanol, 9S0/0 ethanol, then allowed to air dry. 
Slides were stored at -2OoC prior to hybridization. Prehybridization treatments 
were designed to increase penetrance of the probe into the tissue and to 
reduce nonspecific binding of the probe to cellular constituents (Bresser & 
Evinger-Hodges, 1987). 
2.3.5.3 In  Situ Hybridization 
Two million counts per minute (cpm) of radiolabeled probe in 40 vl of 
hybridization buffer were applied to each slide and incubated overnight at 540C 
in a humid chamber. Sense probes were included as a control for binding 
specificity. Covenlips were floated off in 2X SSC and slides were treated with 5 
pg/ml RNase A in RNase digestion buffer (0.5 M NaCI, 10 mM Tris (pH 8.0) and 
1 mM EDTA) for 30 minutes. Slides were then transferred to RNase buffer for 
30 minutes, 2X SSC for 4 minutes, 2X SSC/5O0/0 formamide at  5OoC for 20 
minutes then 0.1X SSC at 50% for 15 minutes. Slides were dehydrated in 
ascending ethanols containing 0.3 M ammonium actetate then air dried. Slides 
were dipped in NTB2 photographic emulsion (Eastman Kodak Co., Rochester, 
NY, U.S.A.) diluted 1:l with nanopure water then left to expose at 40C. When 
adequate exposure time was confirmed through test slides, samples slides were 
developed in D-19 Kodak developer (Eastman Kodak Co., Rochester, NY, 
U.S.A.) and fixed with Kodak general fixer (Eastman Kodak Co., Rochester, NY, 
U.S.A.). Slides were lightly counterstained with cresyl violet, dehydrated, 
cleared and mounted with DPX Neutral Mounting Medium (Aldrich, Chemical Co. 
Inc., Milwaukee, WI, U.S.A.). 
2.3.5.4 Determination of Probe Specificity 
To confirm the specificity of the transcribed probes three control 
procedures were performed: 1) Sense transcripts were used in place of 
antisense transcripts in in situ hybridization experiments. No signal was 
detected in these sections. 2) RNase pretreatment of tissue to degrade mRNA 
and test for binding of the antisense probe to other cell components also 
resulted in no signal. 3) The final control was a competition assay to 
demonstrate that radiolabeled probe binding could be effectively competed out 
by non-radiolabeled probe. Various concentrations of unlabeled probe were 
added to a constant amount of radiolabeled probe. Results demonstrated 
consistently decreasing amounts of signal with increasing non-labeled probe 
concentration. All steps in these control procedures were carried out identical to 
the in situ hybridization procedure (see section 2.3.5.3) 
2.3.5.5 Quantification 
mRNA was quantified using an Axioskop microscope (Carl Zeiss, Inc., 
Thornwood, NY, U.S.A.) interfaced to a PC computer using Northern Eclipse 
Image Analysis Software (Empix Imaging Inc., Mississauga, Ontario, Canada). 
Percent area covered by silver grains in individual cells in the prefrontal cortex 
was measured in minimum of 100 cells per animal over three sections per 
animal per experiment. Percent area covered by silver grains in the dentate 
gyrus, CA3 and CAI regions of the hippocampus were measured over the entire 
area in three sections per animal per experiment. Averaged percent area 
values were converted to percent control values and averaged across two 
experiments. All statistical analyses were performed on percent control values. 
Various numbers of animals in each group were analyzed due to availability of 
sections, preservation of regions, and surgery groups included in the 
hybridization experiments. 
2.3.6 Apoptosis Detection 
Terminal deoxynucleotidyl Transferase (TdT) mediated dUTP-biotin nick 
end labeling (TUNEL) is a procedure used to detect fragmented DNA. During 
the process of apoptosis, internucleosomal fragmentation of DNA occurs. The 
generated DNA fragments contain double stranded ends that are accessible for 
the enzymatic incorporation of biotinylated nucleotides. TdT binds to exposed 
3' hydroxyl ends of DNA and synthesizes a labeled polydeoxynucleotide 
molecule (Ben-Sasson et aL, 1995). 
TUNEL was performed using a TACSZ TdT (Fluor) kit (Trevigen Inc., 
Gaithersburg, MD, U.S.A.). Specifically, sections were rehydrated in 0.1 M PBS 
then treated with proteinase K (0.02 pglpl) for 15 minutes to permeablize the 
tissue. Slides were equilibrated in labeling buffer then incubated for 1 hour at 
370C with 50 PI of TdT enzyme (15 units per slide) in labeling buffer in the 
presence of 0.25 mM biotinylated dNTP and 1 mM CO+~. The reaction was 
stopped in 0.01 M EDTA (pH 8.0) and sections were washed in 0.1 M PBS. In  
the dark, 50 p1 of streptavidin-fluorescein (0.005 pg/pl) was added to each slide 
and incubated for 20 minutes at room temperature. Sections were washed in 
0.1 M PBS in the dark then mounted with fluorescent mounting medium (DAKO 
Corporation, Carpinteria, CA, U.S.A.) containing 5 pg/ml bisbenzamide (Hoechst 
33258). Bisbenzamide is a DNA stain that detects apoptosis on the basis of 
nuclear condensation and cytoplasmic compaction. Apoptotic cells were 
visualized under a fluorescent microscope (Carl Zeiss, Inc., Thornwood, NY, 
U.S.A.) using a 495 nm filter for fluorescein detection and a 365 nm filter for 
bisbenzamide. 
Neurodegeneration was also investigated using Fluoro-Jade B 
(received from Dr. L.C. Schmued, National Center for Toxicological Research, 
Jefferson, AR, U.S.A.). Fluoro-Jade B is an anionic fluorescein derivative that 
selectively stains degenerating neurons (Schrnued etd, 1997). It has been 
demonstrated to stain cell bodies, dendrites, axons and axon terminals of 
degenerating neurons, but not healthy neurons, neuropil, myelin or vascular 
elements. The mechanism by which this occurs is unknown, but it is speculated 
that degenerating neurons express a basic molecule to which Fluoro-Jade, a 
strongly acidic molecule, has a high affinity. Briefly, sections were immersed in 
I0/o potassium hydroxide in 80% ethanol for 5 minutes, followed by 2 minutes 
in 70% ethanol, and 2 minutes in nanopure water. To stabilize the Fluoro-Jade 
B fluorescence and reduce background staining slides were immersed in 0.06% 
potassium permanganate for 10 minutes with gentle shaking. Sections were 
washed 2 minutes in nanopure water then stained with 0.0004% Fluoro-Jade B 
solution (made from a 0.01% (w/v) stock diluted in 0.1% (v/v) acetic acid) for 
20 minutes. Sections were washed 3 X 1 minute in nanopure water then 
quickly dried at 500C on a slide warmer. Sections were cleared in xylene, 
mounted with DPX Neutral Mounting Medium (Aldrich, Chemical Co. Inc., 
Milwaukee, WX, U.S.A.). Fluorescence indicative of neurodegeneration was 
viewed under a fluorescent microscope (Carl Zeiss, Inc., Thornwood, NY, 
U.S.A.) using a 495 nm filter. 
2.3.6.1 Quantification 
Four tissue sections from the prefrontal cortex of each animal were 
processed for detection of apoptosis in 2 separate experiments. Apoptotic cells 
were expressed as a percent of the total number of cells counted. A minimum 
of 800 cells per animal per experiment were counted and averaged to obtain 
percent apoptosis values. Total cell number and apoptotic cell number per 
field of view were counted using a 365 nrn filter to visualize bisbenzamide 
fluorescence. Cells were confirmed as apoptotic using a 495 nm fluorescein 
filter to visualize TACS positive nuclei in sections double labeled with 
bisbenzarnide and TUNEL. 
2.4 Statistics 
Two way analysis of variance (ANOVA) (SPSS for Windows, SPSS Inc., 
Chicago, IL, U.S.A.) was used for all statistical analyses. Newman-Keuls post- 
hoc testing was used to explore all significant interactions. I n  the present 
study, a two way analysis of variance resolved whether differences in means 
were due to lesion status (ACSF versus ibotenic acid), treatment (swim stress 
versus control environment) or due to an interaction between status and 
treatment. The first test in the two way ANOVA investigated a main effect of 
status by averaging scores across treatment conditions (control environment 
versus swim stress) to eliminate that source of variability. A significant main 
effect of status indicated that differences existed between ACSF and ibotenic 
acid treated animals irrespective of treatment condition. The second test in the 
two way ANOVA investigated a main effect of treatment by averaging scores 
across lesion status (ACSF versus ibotenic acid). A significant main effect of 
treatment indicated that differences existed between stressed and non- stressed 
animals irrespective of lesion status. The third test in the two way ANOVA was 
a test of interaction, i.e., whether ACSF and ibotenic acid treated animals 
responded differentially to the treatment conditions. When an interaction 
occurred between two independent variables such as lesion status and 
treatment, post hoc tests were performed to determine which components of 
the interaction were significant. 
2.4.1 Behavioral Testing 
Locomotor activity at PND 35 and PND 56 was analyzed by two-way 
ANOVA with repeated measures. Status (ACSF versus ibotenic acid) was a 
between subjects independent variable and age was a within subjects 
independent variable. Photocell beam breaks were the dependent variable. 
The specific question addressed was "do lesion animals exhi bit different 
locomotor activity behavior than sham animals at PND 35 and/or PND 56?" 
2.4.2 Stress Paradigm 
Two way ANOVA with status (ACSF versus ibotenic acid) and treatment 
(control or swim) as independent variables and photocell beam breaks as the 
dependent variable was performed to investigate the effect of lesion status and 
stress on locomotor activity. The specific questions addressed were: "do lesion 
and sham rats exhibit different locomotor activity behavior at PND 75 and do 
lesion animals show increased responsivity to stress as compared to sham 
animals?" 
2.4.3 Detection of mRNA by In Situ Hybridization 
Two way ANOVA with status (ACSF versus ibotenic acid) and treatment 
(control or swim) as independent variables and percent control mRNA as a 
dependent variable was performed to assess the effect of stress on BDNF and 
NMDARl mRNA in lesion and sham animals. Specific questions addressed 
were: "does baseline expression differ between lesion and sham animals, does 
stress affect the expression of BDNF and/or NMDARl mRNA, and do lesion and 
sham animals respond differently to stress?" 
2.4.4 Apoptosis Detection 
Two way ANOVA with status (ACSF versus ibotenic acid) and treatment 
(control or swim) as independent variables and percent apoptosis as a 
dependent variable was performed to assess the effect of stress on cell death in 
lesion and sham rats. Specific questions addressed were: "does baseline 
apoptosis differ between lesion and sham animals, does stress affect the 
amount of apoptosis in lesion and/or sham animals, and do lesion and sham 
animals respond differently to stress?" 
3. RESULTS 
3.1 Behavioral Testing 
This experiment was performed to evaluate the present animal model 
with respect to the criteria established by Lipska and Weinberger in the original 
model (Lipska et& 1993). Animals with postnatal day 7 ibotenic acid lesions 
of the ventral hippocampus have been shown to display postpubertal 
emergence of hyperresponsivity to dopamine mediated behaviors. The test 
used to investigate this effect was open field locomotor activity in response to 
novelty. All animals were tested at both PND 35 (prepubertal) and PND 56 
(postpubertal) with n=45 in the ACSF group and n=24 in the ibotenic acid 
group. There was no significant effect of age (F(1,67)=3.56, p=.06), no 
significant effect of lesion status (ACSF versus ibotenic acid) (F(1,67)=2.50, 
p=.12) and no age by lesion status interaction (F(1,67)=0.50, p=.48). Overall, 
lesion and sham animals demonstrated similar locomotor behavior following 
exposure to a novel environment. This effect was not influenced by the age of 
the animals (see Figure 3.1). 
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Figure 3.1. Total locomotor activity following exposure to a novel 
environment in an open field (the novel environment) paradigm in lesion 
and sham rats. ANOVA resulted in no significant differences between lesion 
and sham animals at PND 35 or PND 56. 
3.2 Stress Paradigm 
Previous characterization of the model (Lipska eta& 1993) 
demonstrated a tendency for hyperresponsivity to stress as evidenced by 
greater increases in locomotor activity in lesion versus sham animals following 
exposure to physiological stress. This experiment was performed to replicate 
the paradigm used by Lipska eta4 (1993) and to determine if lesioned animals 
were hyperresponsive to stress as compared to sham animals in the present 
study. In  addition to allowing comparison to the model established by Lipska 
and Weinberger, the physiological stressor was used to investigate alterations 
in factors potentially involved in schizophrenia. Results were obtained from a 
total of 23 animals in the ACSF - control group, 23 in the ACSF - swim stress 
group, 11 in the ibotenic acid - control environment group and 13 in the 
ibotenic acid - swim stress group. Only behavioral values from animals 
meeting the histological criteria were included in the analysis. Two way ANOVA 
on total photocell beam break values revealed a significant main effect of lesion 
status (ibotenic acid versus ACSF) (F(1,66)=34.97r p<.001) and of treatment 
(swim stress versus control environment) (F(1,66)=26. l g f  p< .001). NO 
interaction was found between lesion status and treatment (F(1166)=Om01r p=.93) 
(see Figure 3.2). Cumulative data in 15 minute intervals, assessed by two way 
ANOVA, revealed a significant within subjects main effect of time 
(F(1166)=740.87r p<.001) as well as a within subjects time by treatment (swim 
stress versus control environment) interaction (F(l,66) = 80.54, p< .OO 1) and a 
within subjects time by lesion status (ACSF versus ibotenic acid) interaction 
(F(1,66)=26.83f p<.001) (see figure 3.3). There was no time by treatment by 
lesion status interaction (F(1,66)=0.58, p=.75). Exploration of the time by lesion 
status interaction revealed significant differences in locomotor activity between 
ACSF and ibotenic acid treated animals at 30 minutes through to 90 minutes 
(p<.001). Exploration of the time by treatment interaction revealed significant 
differences in locomotor activity between animals exposed to swim stress and 
control environment at 15,45, 60, 75 and 90 minutes (pe.001). 
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Figure 3.2. Total locomotor activity in response to swim stress or a 
control environment in lesion and sham animals at PND 75. ANOVA 
revealed a significant main effect of status (ACSF versus ibotenic acid) 
(F=,,,,34.97, p<.001) and a significant effect of treatment (swim stress 
versus a control environment) (F(l,66,=26. 19, p< .001). There was no 
interaction between status and treatment. * indicates significant main 
effects at p< .001. 
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Figure 3.3. Cumulative open field locomotor activity in lesion and sham 
rats following exposure to swim stress or a control environment. ANOVA 
revealed a significant effect of status (ACSF versus ibotenic acid) 
(F(11661=34.97, p<.001), a significant effect of treatment (swim stress 
versus control environment) (F(1,6q=26. 19, p< ,001) and a significant effect 
of time (F(,66,=740.87, p< .001). There was a significant interaction 
between time and treatment (swim stress versus control environment) 
(F(1,66,=80.54, p< .00 1) and a significant interaction between time and 
status (F(1,,,,=26.83, p< .001). There was no time by treatment by status 
interaction. * indicates significant main effects at p< .OO 1. 
3.3 Histology 
Sections through the ventral hippocampus of lesion and sham rats, 
stained with haematoxylin and eosin were assessed for animal inclusion or 
exclusion. Rats infused with ACSF that were included in the study 
demonstrated no observable cell loss in or around the ventral hippocampus 
(see Figure 3.4). Of the total number of animals infused with ACSF, 
approximately 70% were included in further experiments. Animals excluded 
generally showed small rims of unilateral or bilateral cell loss in the CA3 
pyramidal region of the ventral hippocampus; less than 300 V r n  anterior- 
posteriorly and ventro-dorsally. Animals infused with i botenic acid showed 
varying degrees of cell loss in the ventral hippocampus. The dorsal 
hippocampus showed little to no cell loss in included animals, but excluded 
animals treated with i botenic acid often demonstrated dorsal hippocam pal 
damage or ablation, often in conjunction with thalamic damage. This was 
evident in approximately 25% of ibotenic acid treated animals. A small 
percentage of included animals showed narrowing of the polymorphic layer of 
the dentate gyrus resulting from the suprapyramidal and infrapyramidal blades 
of the dentate gyrus approaching each other. There was, however, no 
apparent granule cell loss. Animals in the ibotenic acid treated group were also 
excluded on the basis of unilateral damage only (-1O0/o), limited extent of 
damage not meeting the criteria (-15*/0), or behavioral abnormalities (seizures) 
(40%). Included i botenic acid treated animals showed significant cell loss in 
the CA3 and CAI pyramidal layers of the ventral hippocampus. This region of 
damage averaged a distance of 1 mrn anterior - posterior through the ventral 
hippocampus and was most dramatic in the CA3 region. The ventricular region 
surrounding the hippocampus was greatly enlarged in the majority of animals. 
In  total, approximately 45% of animals infused with i botenic acid were included 
in subsequent in situ hybridization experiments. 
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Figure 3.4. Haematoxylin and eosin stained sections through the 
ventral hippocampus of ACSF and ibotenic acid treated animals. 
Arrows point to areas of major cell loss. Scale bar = 500 pm. 
3.4 Detection of mRNA by In Situ Hybridization 
3.4.1 BDNF mRNA in the Prefrontal Cortex 
This experiment was performed to determine if lesioned animals 
demonstrate alterations in baseline BDNF mRNA in the prefrontal cortex and to 
determine if appropriate regulation of BDNF mRNA is maintained. Sections 
from a total of 19 animals in the ACSF - control environment group, 17 in the 
ACSF - swim stress group, 11 from the ibotenic acid - control environment 
group and 11 from the ibotenic acid - swim stress group were analyzed. Two 
way ANOVA revealed a significant main effect of treatment (swim stress versus 
control environment) (F(llw)=88.43, pe.001) and a significant interaction 
between lesion status (ACSF versus ibotenic acid) and treatment (F(1,~4)=13.03, 
p<.01). There was no main effect for lesion status (F(1154)=0.70, p=.41). 
Exploration of the interaction revealed a significant change in baseline BDNF 
mRNA in lesion versus sham animals (p<.05) and a significantly different 
response to stress in lesion animals as compared to sham (pe.01). Overall, 
BDNF mRNA was reduced in ibotenic acid treated animals to 88% of control 
values (see Figure 3.5) and was increased in both lesion (139%) and sham 
(122%) animals in response to stress. Significantly different responses to 
stress were seen in lesion versus sham animals such that a relative 51% 
increase in BDNF mRNA was demonstrated in ibotenic acid treated animals, 
whereas only a 22% relative increase was demonstrated in sham animals. 
Bright field photomicrographs demonstrating silver grains indicative of BDNF 
mRNA in coronal sections through the prefrontal cortex of lesion and sham rats 
exposed to swim stress and a control environment are seen in Figure 3.6. In 
response to stress, although no cell counts were performed, it appears that 
BDNF mRNA in the prefrontal cortex is upregulated in individual cells in addition 
to detectable levels being observed in a greater number of cells as compared to 
baseline conditions. Ibotenic acid treatment, under control conditions, appears 
to decrease the expression of BDNF mRNA within individual cells. 
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Figure 3.5. BDNF mRNA in the prefrontal cortex. Two way ANOVA revealed 
a significant effect of treatment (control environment vs. forced swim) 
(F(,,,,=88.43, p< ,001) and a significant interaction between treatment and 
lesion status (ACSF vs. i botenic acid) (F,,,,,= 13.03, p< -01). * significant 
with respect to ACSF-Control, p<.05; ** significant with respect to ACSF- 
Control, p<.01; # significant with respect to Ibotenic Acid-Control, pq.01; + 
significant with respect to ACSF-Swim, p< .05. 
Figure 3.6. In  situ hybridization of BDNF mRNA in the 
prefrontal cortex of lesion and sham animals exposed to a 
control environment or swim stress. A) ACSF - control 
environment, B) ACSF - swim stress, C) Ibotenic acid - 
control environment, D) Ibotenic acid - swim stress. Scale 
bar = 100 pm. 
3.4.2 BDNF mRNA in the Dentate Gyrus of the Hippocampus 
This experiment was performed to determine if lesioned animals 
demonstrate alterations in baseline BDNF mRNA in the dentate gyrus of the 
hippocampus and to determine if appropriate regulation of BDNF mRNA is 
maintained during exposure to stress. Sections from a total of 12 animals in 
the ACSF - control environment group, 7 in the ACSF - swim stress group, 6 
from the ibotenic acid - control environment group and 7 from the ibotenic acid 
- swim stress group were analyzed. Two way ANOVA revealed a significant 
main effect of treatment (swim stress versus control environment) 
(F(1,2a,=33.27, p<.001) and a significant interaction between lesion status 
(ACSF versus ibotenic acid) and treatment (F(1,28)=4.30, p<.05)= There was no 
main effect of status (F(1,28)=2.96, p=.10). Exploration of the interaction 
revealed a significant change in baseline BDNF mRNA in lesion versus sham 
animals (p< .OS). Overall, BDNF mRNA in ibotenic acid treated animals was 
reduced to 75% of control values (see Figure 3.7) and was increased to similar 
overall levels following stress in lesion (127OI0) and sham (124%) animals as 
compared to control levels. Relative increases in BDNF mRNA following 
exposure to stress, however, were not equivalent as a 52% increase in ibotenic 
acid treated animals was demonstrated whereas only a 24% increase in sham 
animals was seen. Bright field photomicrographs showing silver grains in 
coronal sections through the dentate gyrus of the hippocampus are seen in 
Figure 3.8. Silver grains indicative of BDNF mRNA are distributed over granule 
cells throughout the granule layer of the dentate gyrus. Following stress, the 
induction of BDNF mRNA appears to be distributed throughout the granular 
region of the dentate gyrus rather than an induction within a specific subset of 
cells. 
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Figure 3.7. BDNF mRNA in the dentate gyrus of the hippocampus. Two 
way ANOVA revealed a significant effect of treatment (control environment 
vs. forced swim) (F(,,,=33.27, p<.001) and a significant interaction 
between treatment and status (ACSF vs. ibotenic acid) (F,,,,=4.30, pc.05). 
* significant with respect to ACSF - Control (pe.05). 
Figure 3.8. In  situ hybridization of BDNF mRNA in the dentate 
gyrus of the hippocampus of lesion and sham animals 
exposed to a control environment or swim stress. A) ACSF - 
control environment, B) ACSF - swim stress, C) Ibotenic acid 
- control environment, D) Ibotenic acid - swim stress. Scale 
bar = 100 pm. 
3.4.3 BDNF mRNA in the CA3 Region of the Hippocampus 
This experiment was performed to determine if lesioned animals 
demonstrate alterations in baseline BDNF mRNA in the CA3 region of the 
hippocampus and to determine if appropriate regulation of BDNF mRNA is 
maintained during exposure to stress. Sections from a total of 9 animals in the 
ACSF - control environment group, 7 in the ACSF - swim stress group, 7 from 
the ibotenic acid - control environment group and 6 from the ibotenic acid - 
swim stress group were analyzed. Two way ANOVA revealed a significant main 
effect of lesion status (ACSF versus ibotenic acid) (F(1125)= 11.46, p< .Ol) and a 
significant main effect of treatment (swim stress versus control environment) 
(F(1,2s)=44.91, p< -00 1). There was no lesion status by treatment interaction 
(F( 1125)=0. 70, p= Al). Overall, neonatal i botenic acid lesions resulted in reduced 
levels of BDNF mRNA in the W region of the hippocampus as compared to 
sham animals (see Figure 3.9). There was a reduction of BDNF mRNA to 70% 
of control levels under baseline conditions. Further contributing to the main 
effect of lesion status, BDNF mRNA was induced in lesioned animals to 123% of 
control following exposure to stress, whereas, sham animals showed an 
induction to 141% of control. Despite the overall lower levels of BDNF mRNA in 
lesioned animals as compared to controls, however, similar relative increases in 
BDNF mRNA following stress were seen; a 53% increase from baseline in 
lesioned animals and a 41% increase in sham animals. Figure 3.10 depicts 
silver grains observed in coronal sections through the W region of the 
hippocampus in lesion and sham animals exposed to swim stress and a control 
environment. Following exposure to stress, a large number of cells in both 
lesion and sham animals showed a strong induction of BDNF mRNA as 
evidenced by the large number of silver grains over individual cells. Under 
basal conditions, the majority of cells throughout the CA3 region of the 
hippocampus showed relatively low levels of BDNF mRNA expression. 
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Figure 3.9. BDNF mRNA in the CA3 region of the hippocampus. Two way 
ANOVA revealed a significant effect of lesion status (ACSF vs Ibotenic Acid) 
( F =  11.6, p< .01) and a significant effect of treatment (control 
environment vs swim stress) (F(1,25,=44.91, pe.001). There was no 
interaction between lesion status and treatment. * indicates a significant 
main effect at  pc.001, # indicates a main effect significant at pe.01. 
Figure 3.10. In  situ hybridization of BDNF mRNA in the CA3 
region of the hippocampus of lesion and sham animals 
exposed to a control environment or swim stress. A) ACSF - 
control environment, B) ACSF - swim stress, C) Ibotenic acid 
- control environment, D) Ibotenic acid - swim stress. Scale 
bar = 100 pm. 
3.4.4 BDNF mRNA in the CAI Region of the Hippocampus 
This experiment was performed to determine if lesioned animals 
demonstrate alterations in baseline BDNF mRNA in the CAI region of the 
hippocampus and to determine if appropriate regulation of BDNF mRNA is 
maintained during exposure to stress. Sections from a total of 8 animals in the 
ACSF - control environment group, 7 in the ACSF - swim stress group, 5 from 
the ibotenic acid - control environment group and 6 from the ibotenic acid - 
swim stress group were analyzed. Two way ANOVA revealed a significant main 
effect of lesion status (ACSF versus ibotenic acid) (F~l,22~=5.67, pe.05) and a 
significant main effect of treatment (swim stress versus control environment) 
(F(l,22)=21.87, p< ,001). There was no lesion status by treatment interaction 
(F(l,22)=0.12, p= -73). Overall, neonatal ibotenic acid lesions appeared to 
decrease levels of BDNF mRNA in the CAI region of the hippocampus as 
compared to sham animals (see Figure 3.11). Baseline BDNF mRNA levels in 
ibotenic acid treated animals was reduced to 74% of control levels. Further 
contributing to the main effect of lesion status was the lesser induction of BDNF 
mRNA in lesion (122%) versus sham (14l0/0) animals following exposure to 
stress. There was, however, no significant difference in the relative degree of 
the upregulation in lesion (48%) and sham (41%) animals. Figure 3.12 depicts 
silver grains indicative of BDNF mRNA in the CAI region of the hippocampus in 
lesion and sham animals exposed to swim stress and a control environment. 
The increase in BDNF mRNA in response to stress appears to result from a 
general increase in BDNF mRNA expression throughout the CAI region of the 
hippocampus rather than specific induction in a subset of cells. The reduction 
in BDNF mRNA in ibotenic acid treated animals also appears to be throughout 
cells of the CAI region rather than a specific downregulation in a subset of 
cells. 
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Figure 3.11. BDNF mRNA in the CAI region of the hippocampus. Two way 
ANOVA revealed a significant effect of lesion status (ACSF vs ibotenic acid) 
(F(1,22,=5.67, p< .O5) and a significant effect of treatment (control 
environment vs. swim stress) (F(1,221= 2 1.87, p< .001). There was no 
interaction between lesion status and treatment. # indicates a main effect 
significant at p< .O5, * indicates a main effect significant at p< ,001. 
Figure 3.12. I n  situ hybridization of BDNF mRNA in the CAI 
region of the hippocampus of lesion and sham animals 
exposed to a control environment or swim stress. A) ACSF - 
control environment, B) ACSF - swim stress, C) Ibotenic acid 
- control environment, D) Ibotenic acid - swim stress. Scale 
bar = 100 pm. 
3.4.5 BDNF mRNA and Locomotor Activity 
Increases in BDNF mRNA have been correlated with increased physical 
activity. For this reason, it was necessary to determine if the increases in BDNF 
mRNA in the animals exposed to swim stress was due to increased physical 
activity. Animals exposed to swim stress were more active during the 15 
minutes of swimming and displayed increased locomotor activity for a minimum 
of 90 minutes following exposure to swim stress. Sham animals appeared to be 
approaching a plateau in activity after 90 minutes (see Figure 3.3, pg. 68) 
whereas, lesioned animals appeared to continue exhibiting locomotor behavior. 
The increase in activity, both amount and duration, may have directly resulted 
in the increase in BDNF mRNA due to swim stress. The possibility that a 
correlation existed was explored in the prefrontal cortex. Results indicated no 
direct relationship between the amount of physical activity and the level of 
BDNF mRNA expressed in lesion or sham animals (see Figure 3.13). 
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Figure 3.13. Relationship between locomotor activity and BDNF mRNA in the 
PFC of lesion and sham rats. No correlation between physical activity, as 
measured by photocell beam breaks, and expression of BDNF mRNA was 
found. 
3.4.6 NMDARl mRNA in the Prefrontal Cortex 
This experiment was performed to determine if neonatal ibotenic acid 
lesions of the ventral hippocampus influence the expression of  NMDARl mRNA 
in the prefrontal cortex of adult rats. The goal was to investigate if basal 
expression was altered and if stress influenced the expression of this subunit. 
If stress affected the expression, it was also important to determine whether 
differential regulation was seen between lesion and sham rats. Sections from a 
total of 12 animals from the ACSF - control environment group, 7 from the 
ACSF - swim stress group, 5 from the ibotenic acid - control environment 
group and 5 from the ibotenic acid - swim stress group were analyzed. Results 
from the two way ANOVA indicated a significant main effect of lesion status 
(ACSF versus ibotenic acid) (F(1,~~,=9.08, pc.01) and a significant main effect of 
treatment (control environment versus swim stress) (F(I,2s1 ~ 8 . 6 4 ,  p< .0 1). 
There was no interaction between lesion status and treatment (F(1,25)=1.30, 
p=.27). Overall, the results demonstrated a significant reduction in NMDARl 
mRNA expression in the prefrontal cortex of rats with neonatal ibotenic acid 
lesions of the ventral hippocampus (see Figure 3.14). Under baseline 
conditions, a 20% reduction compared to control was seen in lesioned animals. 
Swim stress resulted in an increase in the expression of NMDARl mRNA in both 
lesion (10O0/0) and sham (lO8Yi0) animals as compared to baseline levels. The 
relative increase in NMDARl mRNA in response to stress was not significantly 
different between lesion and sham animals with 20°/0 and 8% increases, 
respectively. Figure 3.15 depicts silver grains indicative of NMDARl mRNA in 
the prefrontal cortex in lesion and sham animals exposed to swim stress and a 
control environment. It appears that individual cells show alterations in 
NMDARl mRNA levels and, although cell counts were not performed, that the 
number of cells expressing NMDARl mRNA is not altered in response to stress 
in lesion or sham animals nor in ibotenic acid treated animals under baseline 
conditions. 
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Figure 3.14. NMDARl mRNA in the prefrontal cortex. Two way ANOVA revealed 
a significant effect of lesion status (ACSF vs. ibotenic acid) (F(,,2s)= 9.08, p < -01) 
and a significant effect of treatment (control environment vs. swim stress) 
(Fc1,2,)=8.64, pe.01). There was no interaction between lesion status and 
treatment. * indicates a main effect significant at p<.01. 
Figure 3.15. In  situ hybridization of NMDARl mRNA in the 
prefrontal cortex of lesion and sham animals exposed to a 
control environment or swim stress. A) ACSF - control, B) 
ACSF - swim stress, C) Ibotenic acid - control, D) Ibotenic 
acid - swim stress. Scale bar = 100 pm. 
3.4.7 NMDARl mRNA in the Dentate Gyrus of the Hippocampus 
This experiment was performed to determine if neonatal ibotenic acid 
lesions of the ventral hippocampus influence the expression of NMDARl mRNA 
in the dentate gyrus of the hippocampus of adult rats. The goal was to 
investigate if basal expression was altered and if stress influenced the 
expression of this subunit. I f  stress affected the expression, it was also 
important to determine whether differential regulation was seen between lesion 
and sham rats. Sections from a total of 7 animals from the ACSF - control 
environment group, 7 from the ACSF - swim stress group, 4 from the ibotenic 
acid - control environment group and 3 from the ibotenic acid - swim stress 
group were analyzed. Results indicated a significant main effect of treatment 
(swim stress versus control environment) (F(1,171=14.42, pe.01) and a 
significant interaction between treatment and status (ACSF versus ibotenic acid) 
(F(1,~7)=7.43, p<.OS). There was no main effect of status (F~1,171=1.93, p=.18). 
Overall, the results indicated a decrease in the expression of NMDARl mRNA 
following stress in both lesion (33%) and sham (1So/o) animals as compared to 
non-stressed sham animals (see Figure 3.16). Exploration of the interaction 
revealed a significant increase in the expression of NMDARl mRNA in non- 
stressed ibotenic acid treated animals (157%) as compared to non-stressed 
sham animals. The relative decreases seen in lesion and sham animals in 
response to stress were 90% and 15% respectively. These decreases appear 
to be distributed throughout the granule cell layer of the dentate gyrus as are 
the increases in NMDARl mRNA expression in ibotenic acid treated animals 
under non-stress conditions. Bright field photomicrographs of silver grains 
indicative of NMDARl mRNA in the dentate gyrus of the hippocampus under 
the above conditions are shown in Figure 3.17. 
El Ibotenic Acid-Control 0 Ibotenic Acid-Swim j j 
Figure 3.16. NMDARl mRNA in the Dentate Gyrus of the Hippocampus. 
ANOVA revealed a significant effect of treatment (swim stress vs. control 
environment) (F(l,17,= 14.42, p< .01) and a significant interaction between 
status (ACSF vs ibotenic acid) and treatment (F(1,17)=7.43, p<.05). * indicates 
a main effect significant at pe.01 and # indicates significant with respect to 
ACSF-control at p< .01. 
Figure 3.17. In situ hybridization of NMDARl mRNA in the 
dentate gyrus of the hippocampus of lesion and sham animals 
exposed to a control environment or swim stress. A) ACSF - 
control environment, B) ACSF - swim stress, C) Ibotenic acid 
- control environment, D) Ibotenic acid - swim stress. Scale 
bar = 100 prn. 
3.4.8 NMDARl mRNA in the CA3 Region of the Hippocampus 
This experiment was performed to determine if neonatal ibotenic acid 
lesions of the ventral hippocampus influence the expression of NMDARl mRNA 
in the CA3 region of the hippocampus of adult rats. The goal was to investigate 
if basal expression was altered and if stress influenced the expression of this 
subunit. If stress affected the expression, it was also important to determine 
whether differential regulation was seen between lesion and sham rats. 
Sections from a total of 10 animals from the ACSF - control environment group, 
9 from the ACSF - swim stress group, 6 from the ibotenic acid - control 
environment group and 5 from the ibotenic acid - swim stress group were 
analyzed. Results from the two way ANOVA indicated a significant main effect 
of treatment (swim stress versus control environment) (F(1,26)= 10.88, p<.01) 
but no significant main effect of lesion status (ACSF versus ibotenic acid) 
(F(1,26)=2.03, p= .l7). There was also no interaction between lesion status and 
treatment (F(1,26)=0.05, p=.82). Overall, the results indicated a similar relative 
reduction in NMDARl mRNA expression in the CA3 region of the hippocampus 
in lesion (34%) and sham (30%) animals (see Figure 3.18). The approximate 
10% reduction in NMDARl mRNA in lesion animais under both baseline and 
stress conditions as compared to sham animals under the same conditions was 
not significantly different. The reduction in NMDARl mRNA in response to 
stress appears to result from a general downregulation in individual cells rather 
than a decrease in the number of cells expressing detectable levels of NMDARl 
mRNA. Bright field photomicrographs of silver grains indicative of NM DARl 
mRNA in the CA3 region of the hippocampus of lesion and sham rats exposed 
to swim stress or a control environment are shown in Figure 3.19. 
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Figure 3.18. NMDARl mRNA in the CA3 region of the hippocampus. Two 
way ANOVA revealed a significant main effect of treatment (swim stress vs 
control environment (F(1,26,=10.88, p<.01). There was no effect of lesion 
status (ACSF vs ibotenic acid) and no interaction between lesion status and 
treatment. * indicates a main effect significant at p<.01. 
Figure 3.19. In situ hybridization of NMDARl mRNA in the 
C . 3  region of the hippocampus of lesion and sham animals 
exposed to a control environment or swim stress. A) ACSF - 
control environment, B) ACSF - swim stress, C) Ibotenic acid 
- control environment, D) Ibotenic acid - swim stress. Scale 
bar = 100 pm. 
3.4.9 NMDARl mRNA in the CAI Region of the Hippocampus 
This experiment was performed to determine if neonatal ibotenic acid 
lesions of the ventral hippocampus influence the expression of NMDARl mRNA 
in the CAI region of the hippocampus of adult rats. The goal was to investigate 
if basal expression was altered and if stress influenced the expression of this 
subunit. If stress affected the expression, it was also important to determine 
whether differential regulation was seen between lesion and sham rats. 
Sections from a total of 8 animals from the ACSF - control environment group, 
10 from the ACSF - swim stress group, 5 from the ibotenic acid - control 
environment group and 4 from the ibotenic acid - swim stress group were 
analyzed. Results indicated a significant main effect of treatment (swim stress 
versus control environment) (F(l,u)= 12.85, px.01). There was no significant 
main effect of status (ACSF versus ibotenic acid) (F(1~3)=2.54, p=.13), nor was 
there a significant interaction between lesion status and treatment (F(l,23)=0.22, 
p=.64). Overall, the results indicated a similar relative reduction in NMDARl 
mRNA expression in the CAI region of the hippocampus in lesion (36%) and 
sham (28%) animals in response to stress (see Figure 3.20). The approximate 
10% and 20% reductions in NMDARl mRNA in lesioned animals under baseline 
and stress conditions respectively, were collectively not significantly reduced 
compared to sham animals under the same conditions. The reduction in 
NMDARl mRNA in response to stress appeared to result from a general 
downregulation in individual cells rather than a decrease in the number of cells 
expressing detectable levels of NMDARl mRNA. Bright field photomicrographs 
of silver grains indicative of NMDARl mRNA in the CA1 region of the 
hippocampus of lesion and sham animals exposed to swim stress or a control 
environment are shown in Figure 3.21. 
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Figure 3.20. NMDARl mRNA in the CAI region of the hippocampus. Two 
way ANOVA revealed a significant main effect of treatment (swim stress vs 
control environment) (F(1,231= 12.85, pc .0 1). There was no main effect of 
lesion status (ACSF vs ibotenic acid) and there was no interaction. * 
indicates a main effect significant at p< .01. 
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Figure 3.21. In s i t ~  hybridization of NMDARl mRNA in the 
CAI  region of the hippocampus of lesion and sham animals 
exposed to a control environment or swim stress. A) ACSF - 
control environment, B) ACSF - swim stress, C) Ibotenic acid 
- control environment, D) Ibotenic acid - swim stress. Scale 
bar = 100 pm. 
3.5 Apoptosis in the Prefrontal Cortex 
Apoptosis was investigated to determine whether animals with 
functionally compromised circuitry, neonatal i botenic acid lesions, displayed 
increased levels of apoptosis compared to normal animals. The link between 
cell death and stress and schizophrenia and stress also led to the investigation 
of whether animals with symptoms reminiscent of schizophrenia displayed 
increased apoptosis in response to stress. Sections from a total of 4 animals 
from the ACSF - control environment group, 5 from the ACSF - swim stress 
group, 4 from the ibotenic acid - control environment group and 4 from the 
ibotenic acid - swim stress group were analyzed. Analysis of bisbenzamide 
counts, confirmed by TUNEL staining, by two way ANOVA indicated a significant 
main effect of lesion status (ACSF versus ibotenic acid) (F~1,131=55.30, p<.001). 
There was no significant main effect of treatment (swim stress versus control 
environment (F(l,13)=3.40, p= .O9) nor was there a significant interaction 
between lesion status and treatment (F(1,13)=3.66, pz.08). Overall, the results 
indicated that animals with neonatal ibotenic acid lesions of the ventral 
hippocampus had greater baseline levels of apoptosis (see Figure 3.22). Lesion 
animals demonstrated 12.1% and 14.0% apoptosis under baseline and swim 
stress conditions, respectively, whereas, sham animals demonstrated 9.3% and 
9.2% apoptosis under baseline and swim stress conditions, respectively. 
Apoptosis levels were not significantly altered by acute stress (14.0% in 
lesioned animals versus 9.2% in sham animals). Figure 3.23 depicts 
bisbenzamide staining of cells in the prefrontal cortex of lesion and sham 
animals exposed to a control environment or swim stress. Apoptotic cells are 
characterized by more intense bisbenzamide fluorescence than heal thy cells. In  
addition, apoptotic cells demonstrate condensation of DNA resulting in reduced 
nuclear size compared to healthy cells. Figure 3.24 demonstrates the reliability 
of bisbenzamide staining to detect apoptosis by depicting double-stained TUNEL 
positive neurons and neurons appearing apoptotic by bisbenzamide staining. 
There is overlap in cells demonstrating intense bisbenzamide fluorescence and 
TUNEL positive nuclei. Increased neurodegeneration in animals with neonatal 
ibotenic acid lesions of the ventral hippocampus as compared to sham animals 
was also apparent in Fluoro-Jade stained sections (see Figure 3.25) although no 
quantification was performed. Regions of intense fluorescence indicate regions 
of neuronal degeneration within the prefrontal cortex. 
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Figure 3.22. Percent apoptosis in the prefrontal cortex. Apoptotic cells 
were identified by bisbenzamide staining and confirmed apoptic by TUNEL 
labeling. Two way ANOVA revealed a significant effect of lesion status 
(ACSF vs ibotenic acid) (F(1,13,=55.3, pe.001). There was no interaction. 
* indicates a main effect significant at p<.001. 
Figure 3.23. Bisbenzamide staining of apoptotic neurons in 
the prefrontal cortex. A) ACSF - control, B) ACSF - swim 
stress, C) Ibotenic acid - control, D) Ibotenic acid - swim 
stress. Scale bar = 500 pm. 
Figure 3.24. Comparison of apoptosis detection by 
bisbenzamide staining (A) and TUNEL staining (8) in identical 
areas of the prefrontal cortex. This example is taken from an 
animal with bilateral neonatal ibotenic acid lesions of the 
ventral hippocampus. Scale bar = 100 pm. 
Figure 3.25. Fluoro-Jade B staining indiciating neurodegeneration 
in the prefrontal cortex of ACSF treated animals (A) and ibotenic 
acid treated animals (B) under control environment conditions. 
Scale bar = 100 vrn. 
4- DISCUSSION 
4.1 Behavioral Testing 
Animals with neonatal ibotenic acid lesions of the ventra ippocampus, a 
model of schizophrenia, have previously been shown to be hyperactive in 
locomotor activity paradigms in adulthood, but not prior to adulthood (Lipska et 
aL, 1993). I n  an attempt to replicate this model of schizophrenia-like 
dysconnectivity, locomotor activity in response to a novel environment was 
investigated in prepubertal (PND 35) and postpubertal (PND 56)  lesion and 
sham rats. Lesion and sham rats demonstrated no differences in locomotor 
activity at either of these time points. This suggests that these animals are not 
hyperresponsive to dopamine-mediated behaviors at PND 56 as previously 
reported (Lipska el& 1993). Alternatively, the possibility exists that the delay 
in emergence of hyperresponsivity is increased. Previous reports demonstrate 
that the extent of the lesion is related to the emergence of behavioral 
hyperresponsivity (Lipska & Weinberger, 1995). These authors reported that 
Sprague-Dawley rats with small ventral hippocampal lesions demonstrated no 
emergence of hyperresponsivity at PND 56, whereas rats with large lesions did. 
No other lesion sizes were investigated in Sprague-Dawley rats, however, small 
and large lesions in other rats strains resulted in varying emergence times of 
behavioral hyperresponsivity. This supports the conclusion that a lesion of 
lesser extent than the original model could result in a further delay in the 
emergence of hyperresponsivity. Further support for the claim of a lesser 
lesion extent is the exclusion of any animals with thalamic damage in the 
present study compared to the 25% cohort with a minor rim of thalamic 
damage in the original study (Lipska etd, 1993). I n  the present study, 
thalamic damage was associated with a greater degree of hippocampal damage 
as compared to included animals. Locomotor activity of animals with this 
degree of damage was not examined, however, as the number of animals was 
not sufficient when those with associated dorsal hippocampal ablation, cortical 
damage, and seizures were removed from the cohort. 
Relevant to the suggestion of an increased delay in the emergence of 
behavioral hyperresponsivity is the demonstration of a main effect of lesion 
status at PND 75 in the stress paradigm. This means that collapsed across 
treatment groups, ibotenic acid treated animals are significantly more active 
than ACSF treated animals. Although no direct comparison of ACSF and 
i botenic acid treated animals exposed to a control environment is acceptable 
from a statistical standpoint, the overall results suggest an emergence of 
hyperresponsivity to dopamine-mediated behavion at this time point. This 
supports the conclusion that the extent of the lesion is less than that of the 
original model, and also leads to the conclusion that facets of the original model 
have been replicated. 
The mechanism underlying the delayed emergence of doparnine- 
mediated behavion is unknown, but it has been suggested that the modulation 
of the mesolimbic dopamine system by the hippocampus may not be significant 
until later maturational stages (Lipska etd, 1993). Alternatively, Lipska e td ,  
(1993) suggest that secondary neurodegenerative processes resulting in 
alterations in behavioral expression may occur over time. This leads to the 
suggestion that this neurodevelopmental model is a more comprehensive model 
of factors associated with schizophrenia than first described. The accuracy of 
this suggestion would implicate neurodevelopment, dysconnectivity and 
neurodegeneration in the model, all factors hypothesized to be relevant to 
schizophrenia. This alternative hypothesis also makes plausible the suggestion 
of a further delay in emergence of dopamine hyperresponsivity. It is possible 
that a threshold of neurodegeneration must necessarily be reached before 
behavioral changes manifest. The lesion would not necessarily impact the age 
at which functional hippocampal modulation of the dopaminergic system 
occurs, but rather, secondary neurodegenerative changes could result in a 
diminished functional capacity of this system later in life. 
4.2 Stress Paradigm 
As discussed above, neonatal lesions of the ventral hippocampus appear 
to result in a delayed emergence of dopamine-mediated behaviors, with the 
present study demonstrating an even later emergence than previous reports. 
I n  addition to this difference between the original and the present model, 
Lipska eta& (1993) demonstrated a trend for hyperresponsivity to stress in 
adult animals, a finding not replicated in the present study. A significant 
increase in locomotor activity is demonstrated in response to stress, but the 
relative magnitude of the increase is virtually identical in lesion and sham 
animals. The reason for the difference between the original model and the 
present findings is unknown, but one could speculate that the assumed 
reduction in lesion size in the present study may result in a relative sparing of 
neurons projecting to the prefrontal cortex. As described earlier, the prefrontal 
cortex is known to play a role in stress (Deutch eta& 1990) and lesions of this 
region in adult animals result in hyperresponsivity to stress (Jaskiw & 
Weinberger, 1992). The demonstration that neonatal, but not adult induced, 
ibotenic acid lesions of the ventral hippocampus can result in hyperresponsivity 
to stress indicates that prefrontal cortex function and/or connectivity is 
affected. A reduction in the extent of damage to the hippocampus may result 
in a lesser downstream impairment in the prefrontal cortex, thereby resulting in 
animals better able to respond appropriately to stress than animals in the 
original model. Contrary to this suggestion, however, is the demonstration of 
hyperresponsivity to stress with respect to BDNF mRNA expression in the 
prefrontal cortex (to be discussed later). I n  addition, incremental locomotor 
activity data (Figure 3.3) suggests that a longer time period of behavioral 
monitoring may reveal differences in the response to stress in lesion and sham 
animals. Ninety minutes parallels the monitoring time in the original 
investigation, however, laboratory variances such as specific testing 
environment (light conditions, time of day) and activity measurement units may 
necessitate a longer monitoring time. At  the 75 and 90 minute intervals, the 
lesion and sham animals exposed to a control environment show similar 
increases in locomotor activity. I botenic acid treated animals exposed to swim 
stress, however, show 1.5 to 2 times the number of photocell beam breaks as 
ACSF treated animals exposed to swim stress. The i botenic acid treated 
animals exposed to swim stress, also do not appear to be habituating as quickly 
as the other groups. It is, therefore, possible that hyperresponsivity to stress 
would be revealed following extended monitoring periods. 
The emergence of behavioral hyperresponsivity to stress in postpubertal 
rats is hypothesized to be due to developmental maturation of the prefrontal 
cortex (Lipska e t d ,  1993). During adolescence the synaptic density of the 
prefrontal cortex declines (Huttenlocher, 1979) with synapses on dendritic 
spines of pyramidal neurons accounting for the majority of the decline 
(Bourgeois eta/, 1994). This reduction in synapses on dendritic spines 
suggests a reduction in excitatory input to these neurons as spines are the 
major location of excitatory synapses on pyramidal neurons (Colonnier, 1968, 
Mates & Lund, 1983). Dopaminergic afferents to the prefrontal cortex also 
undergo maturational changes. These afferents form synapses with dendritic 
spines and shafts of pyramidal neurons (Goldman-Rakic e ld ,  1989) as well as 
with GABAergic interneurons (Sesack eld, 1995). There is a rise in the 
density of dopaminergic synapses prior to the decline of synapses on pyramidal 
neuron spines (Lewis, 1997). The pattern of neuronal connectivity and of 
change suggests that dopamine may influence the maturation of pyramidal 
neuron connectivity in the prefrontal cortex. The link between the prefrontal 
cortex, dopamine, glutamate and stress makes it possible that maturational 
changes affecting these variables, in an already compromised system, may 
result in dysregulation, an inability to compensate, and, therefore, emergence 
of hyperresponsivity to stress. Prior to this maturational point, it is assumed 
that functional compensation accounted for the absence of behavioral 
abnormalities (Lipska etal, 1993). A dysregulation of maturational processes 
resulting from the neurodevelopmental lesion, however, would result in 
inappropriate pruning and consequent behavioral and biochemical 
abnormalities. 
4.3 BDNF mRNA Detection 
4.3.1 BDNF mRNA in the Prefrontal Cortex 
The results of the present study demonstrate that basal BDNF mRNA 
levels are reduced in the prefrontal cortex of rats with neonatal ibotenic acid 
lesions of the ventral hippocampus. Reductions in baseline BDNF mRNA 
expression could resu It in alterations in neuronal morphology, specifically 
dendritic atrophy (McCallister eta& 1995), as well as reduced synaptic 
plasticity (Thoenen, 1995) and reduced neuronal survival (Ghosh etal, 1994). 
The inter-relationship between BDNF and the neurotransmitters GABA and 
glutamate also suggests that reductions in basal BDNF mRNA expression could 
relate to alterations in inhibitory and excitatory neurotransmission in the 
prefrontal cortex. Specifically, it has been demonstrated that BDNF expression 
is positively correlated with glutamatergic neurotransmission and negatively 
correlated with GABAergic neurotransmission (Zafra etd, 1990, 1991). A bi- 
directional regulatory relationship exists, however, between these systems. 
This implies that altered BDNF expression can directly influence glutamatergic 
neurotransmission just as g lutamate can directly regulate BDN F expression 
(Kang & Schuman, 1995, Lebmann e ta ,  1994, Levine et& 1995). As will be 
discussed later, this inter-relationship and the reduction in baseline BDNF levels 
can have significant consequences with respect to brain function, synaptic 
connectivity, neurotransmission, and neuronal viability and/or vulnerability. 
Previous investigations using restraint stress demonstrate that stress 
results in a decrease in BDNF expression (Smith el& 1995a, 1995b), 
however, the present study demonstrates a significant upregulation of BDNF 
mRNA following swim stress. In  addition, animals with neonatal ibotenic acid 
lesions demonstrate significantly greater increases in BDNF mRNA expression 
than do sham animals exposed to stress. This finding is contrary to what was 
expected according to previous reports and the hypothesis tested in this study. 
It was hypothesized that animals with lesions modeling schizophrenia would 
show reductions in baseline BDNF, as was demonstrated, and also show 
significantly reduced BDNF mRNA levels as compared to sham animals exposed 
to swim stress. It is well documented that stress increases glutamate release in 
the prefrontal cortex (Moghaddam, 1993) and that glutamate signal 
transdudion can directly increase BDNF expression (Zafra etd ,  1990, 1991). 
It is possible that the increased glutamate release following stress has a direct 
effect of increasing BDNF mRNA, although the results by Smith etaL (1995a, 
1995b) are not in accordance with this conclusion. It is unknown what 
accounts for the discrepancy between the previous reports and the present 
study, however, the possibility of exon-specific probes can be negated. All of 
the probes used were directed against the region of the rat BDNF gene 
encoding the mature protein; a region conserved in all mRNA transcripts. 
Recently, a corroborating report of increased BDNF mRNA in the prefrontal 
cortex following restraint stress was published (Molteni eta& 1999), however 
no comment was made regarding the demonstration of increased BDNF 
following stress compared to the previous reports of its reduction following 
stress. 
The demonstration that lesioned animals exhibit significantly increased 
BDNF mRNA expression compared to sham animals following exposure to stress 
suggests that these animals are hyperresponsive to the effects of stress. I n  
addition to this, one can conclude that the ability to regulate BDNF expression 
is not impaired. The alternative to this conclusion would be that the stability of 
the mRNA species may be differentially effected between treatments. I n  the 
event that BDNF mRNA stability is not altered there are three possible 
explanations for the relative overexpression of BDNF mRNA. First, a relative 
hypewelease of glutamate resulting in a proportional increase in BDN F m RNA 
may occur. Second, a compensatory mechanism in response to increased 
demands on an already compromised system may result in an increase in 
neuroprotetive factors. Third, there may be a dysregulation in the expression 
of BDNF mRNA. This could result from differential promoter usage or from 
altered regulation of splice variants thereby resulting in an inappropriate 
response. The glutamatergic system has been proposed to play a role in 
schizophrenia (see section 1.2.2). This system is also suggested to be 
hypofunctional in the animal model of schizophrenia (Lillrank et& 1996a). Al- 
Amin etd,  (1996) demonstrated that rats with neonatal ibotenic acid lesions 
are hypersensitive to NMDA antagonists, suggesting a possible dysregulation of 
the glutamatergic system. It was concluded that the destruction of 
g lutamatergic projection fi ben results in reduced glutamate release in the 
prefrontal cortex. Investigation of stimulus-induced amino acid release from 
prefrontal cortical and hippocampal slices prepared from adult rats lesioned as 
neonates revealed a reduction in release (Schroeder e t d ,  1999), thereby 
supporting this conclusion. These findings suggest that increased glutamate 
release is not responsible for the increase in BDNF expression, however, 
stimulus-induced alterations in glutamate have not been investigated in vim. 
I n  addition, different stimuli may result in different glutamate release, 
therefore, one cannot conclude definitively that glutamate release is reduced. 
The role that BDNF plays in neuronal protection suggests that its expression 
may be upregulated in response to a threat to the system as is the situation 
with ischemia (Lindvall etal, 1992) and kainic acid toxicity (Zafra etd, 1990). 
The functionally compromised system set up by the neonatal lesion may 
demonstrate increased vulnerability to stress, therefore, protection from 
atrophy and/or death may require a greater upregulation of BDNF to overcome 
the threat. Alternatively, dysregulation of BDNF expression may result from the 
neonatal lesion. Whether this effect is due to specific promoter usage or to 
altered expression of individual splice variants could be investigated through 
the use of probes specific for these variants. Regardless of whether an 
individual BDNF mRNA splice variant is altered or whether the effect is more 
global, the possibility exists that unnecessary overexpression of BDNF mRNA 
may put further stress on the system. It has been reported that overexpression 
of BDNF can potentiate NMDA-induced necrotic cell death, at least under cell 
culture conditions (Koh etal, 1995). It is questionable whether necrotic cell 
death would occur in this system, however, the conditions under which this 
would occur could be present as there is a potential for increased glutamate 
release following stress and a marked increase in BDNF mRNA was 
demonstrated in the present study. 
4.3.2 BDNF mRNA in the Hippocampus 
The hippocampal formation is a heterogeneous structure consisting of six 
cytoarchitechtonically distinct regions: the dentate gyrus, the hippocampus 
proper (CA3, CA2 and CAI fields), the subiculum, the presubiculum, the 
parasubiculum, and the entorhinal cortex (Amaral & Witter, 1995). The major 
input to the dentate gyrus arises from the entorhinal cortex via the 
unidirectional perforant pathway. The dentate gyrus, in turn projects 
unidirectionally to the W field of the hippocampus via mossy fibers. The CA3 
field projects unidirectionally to the CAI field of the hippocampus via the 
Schaffer collaterals. This intrinsic "tri-synaptic" circuit is the major route of 
information transfer within the hippocampal formation, however, other 
connections have also been identified that involve direct communication 
between various hippocampal fields (Amaral & Witter, 1995). The perforant 
pathway projecting to the dentate gyrus is suggested to be a glutamatergic 
pathway (Fonnum, 1970), however, more recent studies indicate other cell 
types including GABAergic neurons also project to the hippocampus via the 
perforant pathway (Germroth eta& 1989). The mossy fiber projections and 
the Schaffer collaterals use glutamate as their primary neurotransmitter as do 
the CAI pyramidal cells (Storm-Mathisen & Fonnum, 1972). I t  is the CAI 
pyramidal cells that are responsible for the majority of extra-hippocampal 
projections including both cortical and subcortical regions (Van Groen & Wyss, 
1990). 
The present study demonstrates a significant reduction in baseline BDNF 
mRNA in the dentate gyrus of the hippocampus in animals with neonatal 
ibotenic acid lesions. An overall reduction in BDNF mRNA expression is also 
seen in both the CA3 and the CAI fields of the hippocampus following the 
neonatal lesion. In  response to stress, however, differences exist between the 
various hippocam pal regions. Although stress consistently increases the 
expression of BDNF mRNA in all regions, only the dentate gyrus demonstrates a 
hyperresponsivity. The relative response to stress in the CA3 and CAI regions 
are comparable in lesion and sham animals, whereas the dentate gyrus of 
lesioned animals demonstrates a significant upregulation of BDNF mRNA 
following exposure to stress as compared to sham animals. 
As discussed above, reductions in BDNF expression can have serious 
consequences on neurotransmission as well as neuronal plasticity and viability. 
The "tri-syna ptic" connectivity of the hippocampus, with the dentate gyrus 
being the first point of information communication, may be significantly 
compromised by alterations in BDNF expression. The system may be able to 
function with relative normality under basal conditions, but the 
hyperresponsivity to  stress in the dentate gyrus may lead to downstream 
abnormalities in neurotransmission and neuronal viability. As discussed 
previously, BDN F can regulate g lutamaterg ic neurotransmission (Kang & 
Schuman, 1995, Lebmann e td ,  1994, Levine etaL, 1995), therefore, 
hyperresponsive expression of BDNF in lesioned animals may result in increased 
glutamatergic neurotransmission throughout the hippocampus. The results of 
stimulus-induced amino acid release in hippocam pal slices from neonatally 
lesioned animals, however, do not support this conclusion (Schroeder etaL, 
1999). I n  the event that glutamate release is not altered by BDNF expression, 
it remains possible that the b a d  reduction seen in lesioned animals may 
produce neuronal atrophy and consequent compromised neurotransmission. 
Under conditions of stress, the increase in BDNF in the dentate gyrus of 
lesioned versus sham rats may be an attempt for additional compensation on 
an already vulnerable system. One may also suggest that differential input to 
the dentate gyrus may account for its hyperresponsivity as compared to the 
CA3 and CAI fields. As described above, the predominant inputs to the CA3 
and CAI fields are glutamatergic whereas the dentate receives both 
glutamatergic and GABAergic input (Fonnum, 1970, Germroth etd,  1989). It 
is also known that BDNF expression is dependent on the balance of 
glutamatergic and GABAergic input (Zafra et d, 1990, 1991). The possibility 
exists, therefore, that alterations in GABAergic neurotransmission following 
exposure to stress in lesioned animals account for the differential regulation of 
BDNF mRNA in the dentate gyrus. 
I n  the hippocampus, as in the prefrontal cortex, the demonstration of 
increased BDNF mRNA expression is contrary to previous reports of the effects 
of stress on BDNF mRNA (Smith etd,  1995a, 1995b). The increase in 
glutamate neurotransmission following exposure to stress would be expected to 
increase BDNF mRNA, and Smith eta,! (1995a, 1995b) report that their results 
were unexpected based on glutamate increase as well as the effect of other 
system stressors, such as ischemia, on BDNF mRNA expression. 
4.3.3 BDNF mRNA and Locomotor Activity 
The previous reports of reduced BDNF mRNA expression following stress 
(Smith etakt 1995a, 1995b), in addition to the demonstration of increased 
BDNF mRNA expression following physical activity (Neeper etaL, 1996) led to 
the investigation of the effect of swim stress and locomotor activity on BDNF 
mRNA expression. Animals lesioned as neonates did appear to exhibit more 
basal activity than their sham counterparts at PND 75, however, they 
demonstrated reduced BDNF mRNA expression. This suggests that basal levels 
of activity did not have a stimulating effect on BDNF mRNA expression. The 
swim stress, however, resulted in a dramatic increase in physical activity as well 
as an increase in BDNF mRNA in both lesion and sham animals. The 15 
minutes of swimming activity, in addition to the enhanced locomotor activity for 
at least 90 minutes following exposure to stress may have been sufficient to 
enhance BDNF mRNA expression. I n  addition, the significant increase in BDNF 
mRNA in lesion versus sham rats exposed to stress could also be explained by 
the suggested increase in physical activity. As discussed above, the lesioned 
animals exposed to stress were 1.5 to 2 times more active than their sham- 
stressed counterparts at later time points in the locomotor activity paradigm. 
The conclusion could be made that these animals also continued to be more 
active once placed back in the home cage, therefore exhibiting an overall 
greater level of physical activity. The assessment of whether locomotor activity 
directly correlated with BDNF mRNA expression demonstrated no direct 
relationship between physical activity and BDNF mRNA expression. This leads 
to the conclusion that the effect of stress on BDNF mRNA is opposite to that 
previously reported (Smith etd,  1995a, 1995b) and that the hyperresponsivity 
seen in the present study is a result of the lesion, not a result of enhanced 
physical activity. 
4.3.4 Significance of Alterations in BDNF mRNA Expression 
As discussed in section 1.5.2, BDNF is an attractive candidate molecule 
in schizophrenia due to its regulation by factors used to treat schizophrenia 
such as ECT and 5-HT2 antagonists (Lindefores &aL, 1995; Nibuya etd, 
1997; Vaidya etaL, 1997). The potential role of BDNF is also supported by its 
reduction by factors associated with first onset such as stress and estrogen 
withdrawal (Smith etd, 1995a, 1995b; Singh etd, 1995). I n  addition, serum 
BDNF is reported to be reduced in schizophrenia (Toyooka eta& 1999), as is 
hippocampal BDNF mRNA (Brouha etd ,  1996). The present study 
demonstrates a reduction in basal BDNF mRNA levels in the prefrontal cortex 
and the hippocampal formation of animals with neonatal ibotenic acid lesions of 
the hippocampus. This finding parallels those in schizophrenia and, therefore, 
adds validity to the model. Increased validity allows for a better basis for 
extrapolation of information gained from the model to the human condition of 
schizophrenia. Reductions in basal BDNF levels could result in alterations in 
neuronal connectivity by producing a situation of increased neuronal atrophy 
and fewer synapses. This situation is supported by the demonstration of 
altered synaptophysin immunoreactivity in the prefrontal cortex of 
schizophrenic patients (Eastwood etd ,  1995a, Glantz & Lewis, 1997). 
Alterations in synaptic density have not been investigated in the model, 
however, the reduction in BDNF mRNA supports this possibility. Glutamatergic 
neurotransmission can also be directly affected by alterations in BDNF (Kang & 
Schuman, 1995, Lebmann etd, 1994, Levine etal, 1995). The relative 
hypoglutamatergic state proposed in schizophrenia is, therefore, in accordance 
with reduced b a d  BDNF. As stated in the hypothesis, reductions in BDNF may 
also increase the vulnerability of neurons to stress. Hyperresponsivity to stress 
is demonstrated by increases in BDNF mRNA in the prefrontal cortex and the 
dentate gyrus. This could be a direct attempt to compensate for the increased 
vulnerability of the system induced by the neonatal lesion. 
4.4 NMDARI mRNA Detection 
4.4.1 NMDARl mRNA in the Prefrontal Cortex 
The results of the present study demonstrate a reduction in the level of 
NMDARl mRNA expression in the prefrontal cortex of lesion versus sham 
animals. Three possible explanations for this reduced expression are proposed. 
First, a general reduction in glutamate neurotransmission via a lesion-induced 
downregulation of receptor expression may occur. Second, a compensatory 
down regulation resulting from increased glutamate release may result in 
reduced NMDARl mRNA expression. Third, an alteration in channel properties 
may result from altered glutamate neurotransmission such that an alternative 
splice variant is expressed in place of NMDARla. Various splice variant probes 
are available, but to date, these variants have not been investigated in the 
model, so this remains a possibility that cannot be ruled out. The second 
suggestion of a compensatory downregulation is not supported by the previous 
demonstration of reduced g lutama te release from prefrontal cortical and 
hippocampal slices from lesioned animals (Schroeder eta& 1999). I n  addition, 
the suggested lesion-induced reduction in glutamatergic projections from the 
hippocampus to the prefrontal cortex also supports an overall reduction in 
glutamate release in the prefrontal cortex of lesioned animals (Lillrank e t d ,  
1996a). The demonstration of reduced BDNF levels in the prefrontal cortex of 
lesioned animals also supports the conclusion that glutamate release is not 
increased as increased glutamate release would result in increased BDNF 
expression. The suggestion that the lesion induces a reduction in glutamatergic 
neurotransmission via receptor downregulation remains a possibility. 
Reductions in NMDARl subunit expression have been reported in schizophrenia 
in both the temporal lobe and the prefrontal cortex (Hirsch etd,  1997, 
Humphries etal, 1996). This reduction was correlated with the severity of 
symptom presentation, but the conclusion could be made that a lesion as seen 
in the model would produce a symptom severity as great or greater than that 
seen in severe schizophrenia. Reduced glutamate receptor subunit expression 
is also in accordance with the NMDA receptor hypofunction theory of 
schizophrenia (Olney & Farber, 1995). The demonstration of reduced NM DARl 
mRNA expression, therefore, supports the hypothesis that the neonatal lesion 
sets up a functionally compromised system. Reductions in glutamate 
neurotransmission via NMDA receptors would result in improper communication 
between neurons and the potential for cell death. Olney and Farber (1995) 
propose that reduced glutamate neurotransmission through the NMDA receptor 
results in downstream disinhibition of excitatory neurotransrnission. This, in 
turn, could result in excitotoxic damage to neurons. As previously stated, 
reduced glutamate release was detected in slices from lesioned animals thus 
suppotting glutamate hypofunction (Schroeder e l  d, 1999). The second part 
of the hypothesis requiring downstream excitotoxicity, however, is difficult to 
reconcile with the overall demonstration of reduced release. In  accordance 
with glutamate receptor hypofunction and excitotoxicity in this model, and 
perhaps in schizophrenia, however is the demonstration BDNF can protect 
against NMDA excitotoxicity (Tremblay eta& 1999). Reductions in BDNF would 
reduce the ability of a system to protect itself from excitotoxic insults, therefore 
resulting in increased cell death and further detriment to the system. This 
would support a progressive course of the disorder. Despite the lack of a 
demonstrable increase in glutamate release, excitotoxicity could still result from 
relatively low levels of glutamate due to the lack of protective elements in place 
and a potentially hypersensitive system. 
I n  addition to a reduction in overall expression of NMDARl mRNA in the 
animals lesioned as neonates, there appears to be an increase in NMDARl 
mRNA in response to stress. This increase is demonstrated in both lesion and 
sham animals to a similar degree. One can, therefore, conclude that although 
lesioned animals demonstrate reduced basal NMDARl mRNA expression, they 
maintain normal regulatory capacity. The reason for the upregulation is not 
known and appears contrary to the expectations based on increased glutamate 
release following stress. It is possible that other factors influence the 
expression of NMDARI, however, very little is known about the interaction 
between stress and NMDA receptors. I f  the increase in NMDARl mRNA 
expression results in a functional increase in NMDA receptors, it is possible that 
this could contribute to stress induced neuronal death. Liu etaL (1996) 
demonstrated a stress-induces increase in lipid peroxidation, protein oxidation 
and nuclear DNA damage. Despite the fact that the relative NMDARl mRNA 
expression is similar following exposure to stress, it is possible that the effect 
on cell death could be more dramatic due to the presence of a functionally 
compromised system in lesion versus sham animals. 
4.4.2 NMDARl mRNA in the Hippocampus 
Investigation of N MDARl mRNA expression in the hippocampus reveals 
that there is a significant upregulation of this gene in the dentate gyrus. This 
result is not paralleled in the CA3 or the CAI region of the hippocampus. The 
reason for the dramatic upregulation is not known, however, one could 
speculate that it is a compensation for reduced glutamate transmission from 
the entorhinal cortex. Glutamate release from this region has not been 
investigated in the model, but reduced release has been demonstrated in 
prefrontal cortical slices and hippocam pal slices obtained from rats with 
neonatal ibotenic acid lesions (Schroeder e t d ,  1999). I f  this is a 
compensatory mechanism, the question remains why no compensatory increase 
is demonstrated in the prefrontal cortex. It is possible that GABAergic input to 
the dentate gyrus also plays a role in regulating the expression of NMDARl 
mRNA, therefore, resulting in differential responses in the prefrontal cortex and 
the dentate gyrus. It is also possible that the downstream regulatory effects 
are different than those seen directly within the lesion site. 
I n  response to stress, all three regions of the hippocampus investigated 
demonstrated a downregulation of NMDARl mRNA. This would be expected as 
a compensatory mechanism following increased circulating levels of 
glucocorticoids. Glucocorticoids are increased in response to stress and can 
result in extensive damage to hippocampal neurons (Sapolsky etal, 1984, 
Watanabe etd, 1992, Woolley etd, 1990). This effect is proposed to be 
mediated by glutamate acting through NMDA receptors (Armanini et a/, 1990). 
The conclusion can be made that despite the neonatal lesion, these animals 
retain the ability to appropriately regulate NMDARl mRNA expression in 
response to stress. Although very little research has been done regarding 
NMDA receptors and stress one report of increased NMDARl mRNA following 
exposure to stress exists (Bartanusz et d, 1995). This is contrary to the 
present findings, however, apparent differences do exist. The stress paradigm 
was restraint stress as opposed to swim stress, and the probe used in the in 
situ hybridization analysis detected all splice variants of the NMDARl subunit 
not only the NMDAR-la variant as in the present study. It is possible that 
splice variants a re differentially regulated under conditions of stress to 
effectively reduce glutamatergic neurotransmission and subsequent neuronal 
atrophy or death. Splice variant regulation would allow maintained expression 
of NMDA receptors with aiterations in electrophysiological properties accounting 
for the effective reduction in neurotransmission . 
4.4.3 Significance of Alterations in NMDARl mRNA Expression 
The demonstrated reduction of NMDARl mRNA in the prefrontal cortex 
suggests that NMDA receptor hypofunction may be a significant factor 
contributing to the behavioral and biochemical changes seen in the model. This 
finding is also in accordance with the demonstration of reduced BDNF mRNA 
expression. These results indicate that the hypothesis has been satisfied as 
they suggest the presence of a functionally compromised system with 
alterations in neurotransmission as well as neuronal viability and vulnerability. 
The results also demonstrate that the ability to regulate NMDARl mRNA is 
maintained and that the effects are regionally specific, not global as evidenced 
by results from the CA3 and CAI hippocampal fields. The effects of stress on 
NMDA receptor subunit expression are not well understood, however, 
similarities to control indicate that the response is not specific to the lesioned 
system. Although the regulation is similar to control, it can not be concluded 
that the lesioned system demonstrates identical susceptibility to stress induced 
damage. 
4.5 Apoptosis in the Prefrontal Cortex 
TUNEL, in combination with bisbenzarnide staining and Fluoro-Jade B 
staining, indicates that there is increased apoptosis in animals with neonatal 
lesions of the ventral hippocampus. I n  the present study, stress did not appear 
to result in increased apoptosis in sham animals as was previously reported (Liu 
e td ,  1996), however, the stress in this study was not as severe as that used 
by these authors. In addition, relatively high levels of baseline apoptosis were 
demonstrated in lesioned and sham animals in the absence of stress. This may 
have masked any effect of stress in sham lesioned animals. The inclusion of 
unoperated controls may have served to establish a lower baseline as would be 
expected under control conditions. It is possible that sham lesioned animals did 
exhibit minor damage not readily detectable in the histological assessment 
which subsequently resulted in increased susceptibility to cell death. As stated, 
there was a significant increase in overall levels of apoptosis in lesioned animals 
and this level was not significantly affected by stress. One can conclude that 
increased apoptosis does occur in a functionally compromised system and may 
serve to further reduce the functionality of the system. In  addition, increased 
apoptosis was not evident in lesioned animals exposed to acute swim stress 
(p=.08), but one cannot definitively conclude that alternate stress paradigms or 
chronic stress would not result in increased cell death. It is also possible that 
long term cumulative effects of stress may result in increased apoptosis and 
this effect may be more relevant to the proposed slow progression of 
schizophrenia (Fenton & McGlashan, 1994, Illowsky etd,  1988, Lieberman et 
a& 1992, Loebel etd ,  1992, Marsh e t d ,  1994, Wyatt, 1991). If 
extrapolations can be drawn, marginal increases in apoptosis would be difficult 
to detect and in addition would not result in dramatic and relatively rapid loss of 
function as is evident in characteristic neurodegenerative diseases such as 
Alzheimer's and Huntington's (Lieberman, 1999). Relatively small increases in 
neuronal loss in combination with human neuron number variability may also 
account for the inability to detect overall changes in neuron number in the 
cortex of schizophrenic patients (Pakkenberg, 1993). 
In  addition to supporting a progression of the course of schizophrenia, 
the demonstration of increased apoptosis in animals with neonatal ibotenic acid 
lesions also has relevance to gender differences in schizophrenia. As previously 
stated, women show a later peak onset time of schizophrenia than men. In 
addition, women show a second peak following the onset of menopause when 
estrogen levels are known to decrease (Hafner e t d ,  1993; Hambrecht eta/, 
1992). Symptom severity is also known to fluctuate with estrogen levels as 
evidenced by premenstrual exacerbation of symptoms, and symptom 
improvement during pregnancy (Chang and Renshaw, 1986, Gerada and 
Reveley, 1988, for review see Seeman, 1996). The demonstration that 
estrogen is neuroprotective (Behl e td ,  1995, Singer etal, 1996, Toung etarl, 
1998) and that increased estrogen improves the symptoms of schizophrenia 
supports a role for neurodegeneration in this disorder. The demonstration of 
increased apoptosis also supports a role for neurodegeneration in 
schizophrenia. As only male rats were used in the model, it would be of 
interest to determine if female rats demonstrate comparable results following 
neonatal ibotenic acid lesions of the hippocampus and if ovariectomy would 
influence susceptibility. 
The demonstration of increased apoptosis is in accordance with the 
demonstration of reduced BDNF mRNA and reduced NMDARl mRNA. Many 
other factors also play impottant roles in apoptosis and it can not be 
conclusively stated that increases in this model are solely due to BDNF and/or 
NMDARl alterations. The conclusion can be drawn, however, that the neonatal 
lesion does produce a functionally compromised system that demonstrates 
alterations in neuron viability. 
5. CONCLUSIONS 
The present results support the hypothesis of a neurodevelopmentally- 
compromised system resulting in significant consequences in adulthood, 
including alterations in neuronal viability and neuronal communication. Based 
on the investigation of BDNF, NMDARl and apoptosis, the results all suggest 
the presence of a functionally compromised system. I n  addition, BDNF and 
NMDARl mRNA results suggest that the system is more susceptible to damage 
induced by stressors. As discussed above, the demonstration of reduced BDNF 
mRNA and NMDARl mRNA parallel previous reports in schizophrenic patients. 
These factors in associa tion with increased a poptosis have significant functional 
consequences that can be related to the symptoms present in schizophrenia. It 
is known that the prefrontal cortex plays an important role in the organization 
of behavior as well as cognitive functions and adaptive processes (Kolb, 1984, 
Rosenkilde, 1983). The negative symptoms expressed in schizophrenia are 
proposed to be deficits in these prefrontal functions and a tentative 
extrapolation from the present results suggests that neurodegenerative factors 
may play a role in their emergence. 
I n  the model, Lipska eta,! (1993) suggested that secondary 
neurodegenerative changes could result in the postpubertal emergence of 
behavioral abnormalities. The present results suggest that neurodegenerative 
changes do exist following neonatal ibotenic acid lesions. The question not 
answered by this investigation was whether increased apoptosis is evident early 
in post lesion development. To account for the emergence of abnormal 
behaviors, and to reach the hypothesized threshold of dysfunction for 
emergence, the neurodegenerative changes would necessarily begin early in 
post-lesion development. The same situation holds true for alterations in BDNF 
and NMDARl mRNA expression. It remains undetermined whether they are 
altered due to changes in adulthood or whether they are a direct result of the 
lesion and occur early in post-lesion development. The question of whether the 
changes demonstrated in the present study are causative or resultant needs to 
be addressed. Regardless of the answer, it appears that these alterations 
result in significant functional consequences. I f  accurate parallels to 
schizophrenia can be drawn, the results indicate the importance of early 
intervention in treatment of schizophrenia to prevent or slow the disease 
progression. A second important consideration derived from this study is the 
mechanism of action of pharmacological agents used in the treatment of 
schizophrenia. While symptoms can be partially controlled with current 
neuroleptics, improvement of patient prognosis could occur through the use of 
drugs specifically targeted to block cell death or to enhance neuronal viability. 
Questions that remain to be answered from this research project include 
whether protein changes parallel the changes in mRNA expression of BDNF and 
NMDARl and what is the specific time course of events leading to these 
changes. Investigation of the BDNF receptor (TrkB) to determine the extent of 
alterations in neurotrophic support would also be of interest. I n  addition, the 
investigation of apoptosis related genes may provide further insight into the 
pathophysiology of schizophrenia. With respect to early treatment intetvention 
in schizophrenia, it would be of interest to determine whether neuroleptics or 
current neuroprotective agents could prevent the emergence of behavioral and 
biochemical changes seen in the model. 
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